1 **The accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review**
2 **and meta-analysis.**
3

4 Lukas E. Brümmer[1]*, Stephan Katzenschlager[2]*, Mary Gaeddert[1], Christian Erdmann[3], Stephani
5 Schmitz[1], Marc Bota[4], Maurizio Grilli[5], Jan Larmann[2], Markus A. Weigand[2], Nira R. Pollock[6], Aurélien
6 Macé[7], Sergio Carmona[7], Stefano Ongarello[7], Jilian A. Sacks[7], Claudia M. Denkinger[1, 8]
7
8 * These authors contributed equally
9
1) Division of Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, Hei-
delberg, Germany
2) Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany
3) FH Muenster University of Applied Sciences, Muenster, Germany
4) Agaplesion Bethesda Hospital, Hamburg, Germany
5) Library, University Medical Center Mannheim, Mannheim, Germany
6) Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA USA
7) FIND, Geneva, Switzerland
8) German Center for Infection Research (DZIF), partner site Heidelberg University Hospital, Heidel-
berg, Germany

Keywords: SARS-CoV-2; Antigen Test; PCR; meta-analysis;
Running Title: Meta-Analysis: Rapid antigen tests for SARS-CoV-2

Corresponding author:
Claudia M. Denkinger
Division of Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, Heidel-
berg, Germany
Claudia.Denkinger@uni-heidelberg.de
+49 6221 56 36637

ABSTRACT

Background: SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDTs) are increasingly being integrated in testing strategies around the world. Studies of the Ag-RDTs have shown variable performance. In this systematic review and meta-analysis, we assessed the clinical accuracy (sensitivity and specificity) of commercially available Ag-RDTs.

Methods and Results: We registered the review on PROSPERO (Registration number: CRD42020225140). We systematically searched multiple databases (PubMed, Web of Science Core Collection, medRvix and bioRvix, FIND) for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 up until April 30th, 2021. Descriptive analyses of all studies were performed and when more than four studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity in comparison to reverse transcriptase polymerase chain reaction testing. We assessed heterogeneity by subgroup analyses, and rated study quality and risk of bias using the QUADAS 2 assessment tool. From a total of 14,254 articles, we included 133 analytical and clinical studies resulting in 214 clinical accuracy data sets with 112,323 samples. Across all meta-analyzed samples, the pooled Ag-RDT sensitivity was 71.2% (95% confidence interval [CI] 68.2 to 74.0) and increased to 76.3% (CI 73.1 to 79.2) if analysis was restricted to studies that followed the Ag-RDT manufacturers' instructions. The LumiraDx showed the highest sensitivity with 88.2% (CI 59.0 to 97.5). Of instrument-free Ag-RDTs, Standard Q nasal performed best with 80.2% sensitivity (CI 70.3 to 87.4). Across all Ag-RDTs sensitivity was markedly better on samples with lower Ct-values, i.e., <20 (96.5%, CI 92.6 to 98.4) and <25 (95.8%, CI 92.3 to 97.8), in comparison to those with Ct ≥25 (50.7%, CI 35.6 to 65.8) and ≥30 (20.9%, CI 12.5 to 32.8). Testing in the first week from symptom onset resulted in substantially higher sensitivity (83.8%, CI 76.3 to 89.2) compared to testing after one week (61.5%, CI 52.2 to 70.0). The best Ag-RDT sensitivity was found with anterior nasal sampling (75.5%, CI 70.4 to 79.9) in comparison to other sample types (e.g., nasopharyngeal 71.6%, CI 68.1 to 74.9) although CIs were overlapping. Concerns of bias were raised across all data sets, and financial support from the manufacturer was reported in 24.1% of data sets. Our analysis was limited by the included studies' heterogeneity in design and reporting, making it difficult to draw conclusions from.

Conclusion: In this study we found that Ag-RDTs detect the vast majority of cases within the first week of symptom onset and those with high viral load. Thus, they can have high utility for diagnostic purposes in the early phase of disease, making them a valuable tool to fight the spread of SARS-CoV-2. Standardization in conduct and reporting of clinical accuracy studies would improve comparability and use of data.

AUTHOR SUMMARY

Why was this study done?

- Antigen rapid diagnostic tests (Ag-RDTs) are considered an important diagnostic tool to fight the spread of SARS-CoV-2
- An increasing number of Ag-RDTs is offered on the market, and a constantly growing body of literature evaluating their performance is available
- To inform decision makers about the best test to choose, an up to date summary of their performance is needed

What did the researchers do and find?

- On a weekly basis, we search multiple data bases for evaluations of Ag-RDTs detecting SARS-CoV-2 and post the results on www.diagnosticsglobalhealth.org
- Based on the search results up until April 30th, 2021, we conducted a systematic review and meta-analysis, including a total of 133 clinical and analytical accuracy studies
- Across all meta-analyzed studies, when Ag-RDTs were performed according to manufacturers' recommendations, they showed a sensitivity of 76.3% (CI 73.1 to 79.2), with the LumiraDx (sensitivity 88.2%, CI 59.0 to 97.5) and of the instrument-free Ag-RDT Standard Q (74.9% sensitivity, CI 69.3 to 79.7) performing best.
- Across all Ag-RDTs, sensitivity increased to 95.8% (CI 92.3 to 97.8) when restricting the analysis to samples with high viral loads (i.e., a Ct-value <25) and to 83.8% (CI 76.3 to 89.2) when tests were performed on patients within the first week after symptom onset

What do these findings mean?

- Ag-RDTs detect the vast majority of cases within the first week of symptom onset and those with high viral load. Thus, they can have high utility for diagnostic purposes in the early phase of disease
- Out of all assessed tests, the Lumira Dx showed the highest accuracy. The Standard Q was the best performing test when only considering those that don't require an instrument
- A standardization of reporting methods for clinical accuracy studies would enhance future test-comparisons

ABBREVIATIONS

Ag-RDT   = antigen rapid diagnostic test

AN/MT   = anterior nasal or mid-turbinate

BAL/TW   = bronchoalveolar lavage or throat wash

CI   = confidence interval

Ct-value   = cycle threshold value

FIND   = Foundation for Innovative New Diagnostics

FP   = false positive

FN   = false negative

IFU   = instructions for use

LRT   = lower respiratory tract

ML   = milliliter

N   = sample size

NP   = nasopharyngeal

OP   = oropharyngeal

PFU   = plaque forming units

RT-PCR   = reverse transcriptase polymerase chain reaction

TP   = true positive

TN   = true negative

VTM/UTM   = viral or universal transport medium

INTRODUCTION

As the COVID-19 pandemic continues around the globe, antigen rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 are seen as an important diagnostic tool to fight the virus' spread [1,2]. The number of Ag-RDTs on the market is increasing constantly [3]. Initial data from independent evaluations suggests that the performance of SARS-CoV-2 Ag-RDTs may be lower than what is reported by the manufacturers. In addition, Ag-RDT accuracy seems to vary substantially between tests [4-6].

With the increased availability of Ag-RDTs, an increasing number of independent validations have been published. Such evaluations differ widely in their quality, methods and results, making it difficult to assess the true performance of the respective tests [7]. To inform decision makers on the best choice of individual tests, an aggregated, widely available and frequently updated assessment of the quality, performance and independence of the data is urgently necessary. While other systematic reviews have been published, they only include data up until Nov 2020 [8-11], exclude preprints [12], or were industry sponsored [13]. In addition, only one assessed the quality of studies in detail, with data up until Nov, 2020 [7,11].

With our systematic review and meta-analysis, we aim to close this gap in the literature and link to a website (www.diagnosticsglobalhealth.org) that is regularly updated.

METHODS

We developed a study protocol following standard guidelines for systematic reviews [14,15], which is available in the Supplement (S15). We have also completed the PRISMA checklist, which can be found in the Supplement (S1_PRISMA_Checklists) as well. Furthermore, we registered the review on PROSPERO (Registration number: CRD42020225140).

SEARCH STRATEGY

We performed a search of the databases PubMed, Web of Science, medRxiv and bioRxiv using search terms that were developed with an experienced medical librarian (MauG) using combinations of subject headings (when applicable) and text-words for the concepts of the search question. The main search terms were "Severe Acute Respiratory Syndrome Corona-virus 2", "COVID-19", "Betacoronavirus", "Coronavirus" and "Point of Care Testing". The full list of search terms is available in the Supplement (S2). We also searched the FIND website (https://www.finddx.org/sarscov2-eval-antigen/) for relevant studies manually. We performed the search up until April 30th, 2021. No language restrictions were applied.

INCLUSION CRITERIA

We included studies evaluating the accuracy of commercially available Ag-RDTs to establish a diagnosis of a SARS-CoV-2 infection against reverse transcriptase polymerase chain reaction (RT-PCR) or cell culture as reference standard. We included all study populations irrespective of age, presence of symptoms, or the study location. We considered cohort studies, nested cohort studies, case-control or cross-sectional studies and randomized studies. We included both peer reviewed publications and preprints.

We excluded studies in which patients were tested for the purpose of monitoring or ending quarantine. Also, publications with a population size smaller than 10 were excluded. Although the

size threshold of 10 is arbitrary, such small studies are more likely to give unreliable estimates of

sensitivity or specificity.

INDEX TESTS

Ag-RDTs for SARS-CoV-2 aim to detect infection by recognizing viral proteins. Most Ag-RDTs use

specific labeled antibodies attached to a nitrocellulose matrix strip, to capture the virus antigen. Suc-

cessful binding of the antibodies to the antigen is either detected visually (through the appearance of

a line on the matrix strip (lateral flow assay)) or requires a specific reader for fluorescence detection.

Microfluidic enzyme-linked immunosorbent assays have also been developed. Ag-RDTs typically pro-

vide results within 10 to 30 minutes [6].

REFERENCE STANDARD

Viral culture detects viable virus that is relevant for transmission but is available in research set-

tings only. Since RT-PCR tests are more widely available and SARS-CoV-2 RNA (as reflected by RT-PCR

cycle threshold (Ct) value) highly correlates with SARS-CoV-2 antigen quantities, we considered it an

acceptable reference standard for the purposes of this systematic review [16]. It is of note that there

is currently no international standard for the classification of viral load available.

STUDY SELECTION AND DATA EXTRACTION

Two reviewers (LEB and CE, LEB and SS or LEB and MB) reviewed the titles and abstracts of all

publications identified by the search algorithm independently, followed by a full-text review for

those eligible, to select the articles for inclusion in the systematic review. Any disputes were solved

by discussion or by a third reviewer (CMD).

A full list of the parameters extracted is included in the Supplement (S14) and the data extrac-

tion file is available upon request. Studies that assessed multiple Ag-RDTs or presented results based

on differing parameters (e.g., various sample types) were considered as individual data sets.

At first, four authors (SK, CE, SS, MB) extracted five randomly selected papers in parallel to align

data extraction methods. Afterwards, data extraction and the assessment of methodological quality

and independence from test manufacturers (see below) were performed by one author per paper

(SK, CE, SS, MB) and controlled by a second (LEB, SK, SS, MB). Any differences were resolved by dis-

cussion or by consulting a third author (CMD).

STUDY TYPES

We differentiated between clinical accuracy studies (performed on clinical samples) or analytical

accuracy studies (performed on spiked samples with a known quantity of virus). Analytical accuracy

studies can differ widely in methodology, impeding an aggregation of their results. Thus, while we

extracted the data for both kinds of studies, we only considered data from clinical accuracy studies as

eligible for the meta-analysis. Separately, we summarized the results of analytical studies and com-

pared them with the results of the meta-analysis for individual tests.

ASSESSMENT OF METHODOLOGICAL QUALITY

The quality of the clinical accuracy studies was assessed by applying the QUADAS-2 tool [17].

The tool evaluates four domains: patient selection, index test, reference standard, and flow and tim-

ing. For each domain, the risk of bias is analyzed using different signaling questions. Beyond the risk

of bias, the tool also evaluates the applicability of the study of each included study to the research

question for every domain. The QUADAS 2 tool was adjusted to the needs of this review and can be

found in the Supplement (S3).

ASSESSMENT OF INDEPENDENCY FROM MANUFACTURERS

We examined whether a study received financial support from a test manufacturer (including

the free provision of Ag-RDTs), whether any study author was affiliated with a test manufacturer, or

a respective conflict of interest was declared. Studies were judged not to be independent from the

test manufacturers if at least one of these aspects was present, otherwise they were considered to

be independent.

STATISTICAL ANALYSIS AND DATA SYNTHESIS

We extracted raw data from the studies and recalculated performance estimates where possi-

ble based on the extracted data. The raw data can be found in the Supplement (S4). We prepared

forest plots for the sensitivity and specificity of each test and visually evaluated the heterogeneity

between studies. If four or more data sets were available with at least 20 positive RT-PCR samples

per data set for a predefined analysis, a meta-analysis was performed. We report point estimates of

sensitivity and specificity for SARS-CoV-2 detection compared to the reference standard along with

95% confidence intervals (CI) using a bivariate model (implemented with the 'reitsma' command

from the R package "mada" version 0.5.10). When there were less than four studies for an index test,

only a descriptive analysis was performed and accuracy ranges were reported. In sub-group analyses

where papers presented data only on sensitivity, a univariate random-effects inverse variance meta-

analysis was done (using the 'metagen' command from the R package "meta" version 4.11-0). We

predefined the following subgroups for meta-analysis: by Ct-value range, by sampling and testing

procedure in accordance with manufacturer's instructions as detailed in the instructions for use

(henceforth called IFU-conforming) vs. not IFU-conforming, age (<18; ≥18), sample type, by presence

or absence of symptoms, symptom duration (<7 days vs. ≥7 days), by viral load and by type of RT-PCR

used.

In an effort to use as much of the heterogeneous data as possible, the cut-offs for the Ct-value

groups were relaxed by 2-3 points within each range. The <20 group included values reported up to

≤20, the <25 group included values reported as ≤24 or <25 or 20-25, the <30 group included values

from ≤29 to ≤33 and 25-30. The ≥25 group included values reported as ≥25 or 25-30, the ≥30 group

included values from ≥30 to ≥35. For categorization by sample type, we assessed (1) nasopharyngeal

(NP) alone or combined with other (e.g., oropharyngeal (OP)), (2) OP alone, (3) anterior nasal or mid-

turbinate (AN/MT), (4) a combination of bronchial alveolar lavage and throat wash (BAL/TW) or (5)

saliva. For categorization by age, the pediatric group included values reported as <16 or <18, whereas

values reported as ≥16 or ≥18 were included in the adult group. Analyses were preformed using R

4.0.3 (R Foundation for Statistical Computing, Vienna, Austria).

We aimed to do meta-regression to examine the impact of covariates including symptom dura-

tion and Ct-value range. We also performed the Deeks' test for funnel-plot asymmetry as recom-

mended to investigate publication bias for diagnostic test accuracy meta-analyses ([18], using the

'midas' command in Stata version 15); a p-value<0.10 for the slope coefficient indicates significant

asymmetry.

SENSITIVITY ANALYSIS

Two types of sensitivity analyses were planned: an estimation of sensitivity and specificity ex-

cluding case-control studies, and estimation of sensitivity and specificity excluding non-peer-

reviewed studies. We compared the results of each sensitivity analysis against overall results to as-

sess the potential bias introduced by considering case-control studies and non-peer reviewed stud-

ies.

 RESULTS

 SUMMARY OF STUDIES

The systematic search resulted in 14,254 articles. After removing duplicates, 8,921 articles were

screened, and 266 papers were considered eligible for full-text review. Of these, 148 were excluded

because they did not present primary data [13,19-131] or the Ag-RDT was not commercially available

[16,132-164], leaving 133 studies to be included in the systematic review (Fig 1) [4,165-296].

At the end of the data extraction process, 37 studies were still in preprint form

[4,171,173,174,177,180,190,192,201,204,205,207,211,214-

216,218,220,222,223,225,227,231,233,234,238,240,244,247,253,257,265,267,284,287,290,293]. All

studies were written in English, except for two in Spanish [175,280]. Out of the 133 studies, nine

reported analytical accuracy [173,191,198,208,227,256,274,275,282] and the remaining 124 report-

ed clinical accuracy.

The clinical accuracy studies were divided into 214 data sets, while the nine analytical accuracy

studies accounted for 62 data sets. A total of 61 different Ag-RDTs were evaluated (48 lateral flow

with visual readout, twelve requiring an automated reader), with 56 being assessed in a clinical accu-

racy study. 39 studies reported data for more than one test and 19 studies of these conducted a

head-to-head assessment, i.e., testing at least two Ag-RDTs on the same sample or participant. The

reference method was RT-PCR in all except one study, which used viral culture [281].

The most common reasons for testing were the occurrence of symptoms (55/19.9% of data

sets), screening independent of symptoms (19/6.9%) and close contact to a SARS-CoV-2 confirmed

case (10/3.6%). In 79 (28.6%) of the data sets, persons were tested due to more than one of the rea-

sons mentioned before and for 163 (59.1%) the reason for testing was unclear.

In total, 113,242 Ag-RDTs were performed, 112,323 (99.2%) in clinical accuracy studies and 919

(0.8%) in analytical accuracy studies. In the clinical accuracy studies, the mean number of samples

per study was 525 (Range 16 to 6,954). Only 4,752 (4.2%) tests were performed on pediatric samples

and 21,351 (18.9%) on samples from adults. For the remaining 87,139 (76.9%) samples it was not

specified whether they originate from adults or children. Symptomatic patients comprised 36,981

(32.7%) samples, 32,799 (29.0%) samples originated from asymptomatic patients, and for 42,462

(38.4%) samples the patient's symptom status could not be identified. The most common sample

type evaluated was NP and mixed NP/OP (67,036 samples, 59.2%), followed by AN/MT (27,045 sam-

ples, 23.9%). There was substantially less testing done for the other sample types, with 6,254 (5.5%)

tests done from OP samples, 1,351 (1.2%) from saliva, 219 (0.2%) from BAL/TW and for 11,337

(10.0%) tests we could not tell the type of sample.

Of the data sets assessing clinical accuracy, 89 (41.6%) performed testing according to the man-

ufacturers' recommendations (i.e., IFU-conforming), while 100 (46.7%) were not IFU-conforming and

for 25 (11.7%) it was unclear. The most common deviations from the IFU were (1) use of samples

that were prediluted in transport media not recommended by the manufacturer (80 data sets; seven

unclear), (2) use of banked samples (60 data sets; 14 unclear) and (3) a sample type that was not

recommended for Ag-RDTs (17 data sets; 8 unclear).

A summary of the tests evaluated in clinical accuracy studies, including study author, sample

size, sample type, sample condition and IFU conformity, can be found in Table 1. The Panbio test by

Abbott Rapid Diagnostics (Germany; henceforth called Panbio) was reported the most frequently

with 39 (18.2%) data sets and 28,089 (25.0%) tests, while Standard Q test by SD Biosensor (South

Korea; distributed in Europe by Roche, Germany; henceforth called Standard Q) was assessed in 37

(17.3%) data sets with 16,820 (15.0%) tests performed. Detailed results for each clinical accuracy

study are available in the Supplement (S 4).

METHOLOGICAL QUALITY OF STUDIES

The findings on study quality using the QUADAS 2 tool are presented in Fig 2. In 190 (88.8%) da-

ta sets a relevant patient population was assessed. However, for only 44 (20.6%) of the data sets the

patient selection was considered representative of the setting and population chosen (i.e., they

avoided inappropriate exclusions, a case-control design and enrollment occurred consecutive or ran-

domly).

The conduct and interpretation of the index tests was considered to have low risk for introduc-

tion of bias in 113 (52.8%) of data sets (through e.g., appropriate blinding of persons interpreting the

visual read-out). However, for 99 (46.3%) of data sets sufficient information to clearly judge the risk

of bias was not provided. In only 89 (41.6%) of data sets the Ag-RDTs were performed according to

IFU, while 100 (46.7%) were not IFU-conforming, potentially impacting the diagnostic accuracy (for

25 (11.7%) of data sets the IFU status was unclear).

In 81 (37.9%) of data sets the reference standard was performed before the Ag-RDT, or the op-

erator conducting the reference standard was blinded to the Ag-RDT results, resulting in a low risk of

bias. In almost all other data sets (132/61.7%) this risk could not be assessed due to missing data. The

applicability of the reference test was judged to be of low concern for all data sets, as cell culture or

RT-PCR are expected to adequately define the target condition.

In 209 (97.7%) data sets, the sample for the index test and reference test were obtained at the

same time, while this was unclear in five (2.3%). All samples included in a data set were applied to

the same type of RT-PCR in 145 (67.8%) data sets, while different types of RT-PCR were used within

the same data set in 50 (23.4%) data sets. For 19 (8.9%), it was unclear. Furthermore, for 11 (5.1%) of

data sets, there was a concern that not all selected patients were included in the analysis.

Finally, 32 (24.1%) of the studies received financial support from the Ag-RDT manufacturer and

in another nine (6.8%) employment of the authors by the manufacturer of the Ag-RDT studied was

indicated. Overall, a conflict of interest was found in 33 (24.8%) of the studies.

DETECTION OF SARS-COV-2 INFECTION

Out of 214 clinical data sets (from 124 studies), 20 were excluded from the meta-analysis, as

they included less than 20 RT-PCR positive samples. Further 21 data sets were missing either sensitiv-

ity or specificity and were only considered for univariate analyses. Across the remaining 173 data

sets, including any test and type of sample, the pooled sensitivity and specificity were 71.2% (95%CI

68.2 to 74.0) and 98.9% (95%CI 98.6 to 99.1), respectively. If testing was performed in conformity

with IFU, sensitivity increased to 76.3% (95%CI 73.1 to 79.2) compared to not IFU-conforming testing

with a sensitivity of 65.9% (95%CI 60.6 to 70.8). Pooled specificity was similar in both groups (99.1%

(95% CI 98.8-99.4)and 98.3% (95% CI 97.7 to 98.8), respectively).

ANALYSIS OF SPECIFIC TESTS

Based on 119 data sets with 71,424 tests performed, we were able to perform bivariate meta-

analysis of the sensitivity and specificity for twelve different Ag-RDTs (Fig 3A). Across these, pooled

estimates of sensitivity and specificity on all samples were 72.1% (95%CI 68.8 to 75.3) and 99.0%

(95% CI 98.7 to 99.2), which were very similar to the overall pooled estimate across all meta-analyzed

data sets (71.2% and 98.9%, above).

The highest pooled sensitivity was found for the SARS-CoV-2 Antigen Test by LumiraDx (United

Kingdom; henceforth called LumiraDx) and the Lumipulse G SARS-CoV-2 Ag by Fujirebio (Japan;

henceforth called Lumipulse G) with 88.2% (95% CI 59.0 to 97.5) and 87.2% (95% CI 78.0 to 92.9),

respectively. The Sofia SARS Antigen FIA by QUIDEL (California, US; henceforth called Sofia) had a

pooled sensitivity with 77.4% (95% CI 74.2 to 80.3). Of the non-instrument tests, the Standard Q and

the Standard Q nasal test by SD Biosensor (South Korea; distributed in Europe by Roche, Germany;

henceforth called Standard Q nasal) performed best with a pooled sensitivity of 74.9% (95% CI 69.3

to 79.7) and 80.2% (95% CI 70.3 to 87.4), respectively. The pooled sensitivity for Panbio was 71.8%

(95%CI 65.4 to 77.5). From all Ag-RDTs, the COVID-19 Ag Respi-Strip by Coris BioConcept (Belgium;

henceforth called Coris) had the lowest pooled sensitivity of 40.0% (95% CI 28.7 to 52.4).

The pooled specificity was above 98% for all of the tests, except for the Standard F by SD Bio-

sensor (South Korea) and Lumipulse G with specificities of 97.7% (95% CI 96.6 to 98.5) and 96.7%

(95% CI 88.6 to 99.1), respectively. Hierarchical summary receiver-operating characteristic for Stand-

ard Q and LumiraDx are available in the Supplement (S6).

Three Ag-RDTs did not have sufficient data to allow for a bivariate meta-analysis, wherefore a

univariate analysis was conducted (Fig 3B). For the INNOVA SARS-CoV-2 Antigen Rapid Qualitative

Test by Innova Medical Group (California, US) this resulted in a pooled sensitivity and specificity of

76.1% (95% CI 68.1 to 84.1) and 99.4% (95% CI 98.7 to 100), respectively. For the NADAL by NAL von

Minden (Germany) and the COVID-19 Rapid Antigen Visual Read by SureScreen (United Kingdom),

sufficient data was only available to analyze sensitivity, resulting in polled sensitivity estimates of

58.4% (95% CI 29.2 to 87.6) and 58.0% (95% CI 38.3 to 77.6) and, respectively.

The remaining 35 Ag-RDTs did not present sufficient data for neither a uni- nor a bivariate meta-

analysis. However, 9/35 have results presented in more than one data set and are summarized in

Table 2. Herein, the widest ranges of sensitivity were found for the ESPLINE SARS-CoV-2 by Fujirebio

(Japan) with sensitivity reported between 8.1% and 80.7%, and the RIDA®QUICK SARS-CoV-2 Antigen

by R-Biopharm (Germany) with sensitivity between 39.2% and 77.6%, both with three data sets each.

In contrast, two other test with two data sets each showed the least variability in sensitivity: the

Zhuhai Encode Medical Engineering, SARS-CoV-2 Antigen Rapid Test (China) reported sensitivity be-

tween 74.0% and 74.4% and the COVID-19 Rapid Antigen Flourescent by SureScreen (UK) reported

sensitivity between 60.3% and 69.0%. However, for both tests both data sets originated from the

same studies. Overall, the lowest sensitivity range was reported for the SARS-CoV-2 Antigen Rapid

Test by MEDsan (Germany) with 36.5% to 45.2% across two data sets. The specificity ranges were

above 96% for most of the tests. A notable outlier was the 2019-nCov Antigen Rapid Test Kit by

Shenzhen Bioeasy Biotechnology (China; henceforth called Bioeasy), reporting the worst with a speci-

ficity as low as 85.6% in one study. Forest plots for the data sets for each Ag-RDT are provided in the

Supplement (S5). The remaining 26 Ag-RDTs that were evaluated in one data set only are included in

Table 1 and Supplement (S5).

In total, 16 studies accounting for 53 data sets conducted head-to-head clinical accuracy evalua-

tions of different tests using the same sample(s) from the same participant. These data sets are un-

derlined in Table 1; 15 such studies included more than 100 samples, and one study included too few

samples to draw clear conclusions [286]. Four studies performed their head-to-head evaluation as

per manufacturers' instructions and on symptomatic patients. Across three of them, the Standard Q

(sensitivity 73.2% to 91.2%) and the Standard Q nasal (sensitivity 82.5% to 91.2%) showed a similar

range of sensitivity [207,215,271]. The fourth reported a sensitivity of 56.4% (95% CI 44.7 to 67.6) for

the Biocredit Covid-19 Antigen rapid test kit by RapiGEN (South Korea; henceforth called Rapigen)

and 52.6% (95% CI 40.9 to 64) for the SGTi-flex COVID-19 Ag by Sugentech (South Korea) [233].

All other head-to-head comparisons were not IFU-conforming. In one of these, the Rapid

COVID-19 Ag Test by Healgen (sensitivity 77.1%) performed better than the Standard Q and Panbio

(sensitivity 69.8% and 67.7%, respectively) [178]. In contrast to the overall findings of the meta-

analysis above, two other head-to-head studies found that both the Standard Q (sensitivity 43.6%

and 49.4) and Panbio (sensitivity 38.6% and 44.6%) had lower performance than the CLINITEST® Rap-

id COVID-19 Antigen Test by Siemens Healthineers (Germany; henceforth called Clinitest), which

reported sensitivities 51.5% and 54.9% [167,279]. However, another study found both the Standard

Q and Panbio (sensitivity 81.0% and 82.9%, respectively) to have a higher accuracy than the Sofia

(sensitivity 80.4%) [196].

SUBGROUP ANALYSIS

The results are presented in Fig 4. Detailed results for the subgroup analysis are available in the

Supplement (S7 to 11).

Subgroup analysis by Ct-values

High sensitivity was achieved for Ct-values <20 with 96.5% (95% CI 92.6 to 98.4). The pooled

sensitivity for Ct-values <25 was markedly better at 95.8% (95% CI 92.3 to 97.8) compared to the

group with Ct ≥ 25 at 50.7% (95% CI 35.6 to 65.8). A similar pattern was observed when the Ct-values

were analyzed using cut-offs <30 or ≥30, resulting in a sensitivity of 79.9% (95% CI 70.3 to 86.9) and

20.9% (95% CI 12.5 to 32.8), respectively (Fig 4A).

In addition, it was possible to meta-analyze test specific pooled sensitivity for the Panbio: 97.7%

sensitivity (95% CI 95.3 to 98.9) for Ct-value <20, 95.8% (95% CI 92.3 to 97.8) for Ct-value <25 and

83.4% (95% CI 69.1 to 91.9) for Ct-value <30. For Ct-value ≥25 sensitivity was 61.2% (95% CI 38.8 to

79.7) and 30.5% (95% CI 16.0 to 50.4) for Ct-value ≥30. For the other Ag-RDTs only limited data was

available, which is presented in the supplements (S10).

Subgroup analysis by IFU conformity

The summary results are presented in Fig 4B. When assessing only studies with an IFU-

conforming testing, pooled sensitivity from 81 datasets with 49,643 samples was 76.3% (95% CI 73.1

to 79.2). When not IFU-conforming sampling (75 data sets, 31,416 samples) was performed sensitivi-

ty decreased to 65.9% (95% CI 60.6 to 70.8).

For five tests it was possible to calculate pooled sensitivity estimates only including data sets

with an IFU-conforming testing: Panbio (sensitivity of 76.5% (95% CI 69.5 to 82.3); 17 data sets,

12,856 samples), Standard Q (sensitivity of 79.3% (95% CI 73.5 to 84.1); 15 data sets, 6,584 samples),

BinaxNOW (sensitivity of 61.8% (95% CI 48.0 to 74.0); 4 data sets, 8,163 samples), Rapigen (sensitivi-

ty of 67.1% (95% CI 50.4 to 80.4); 4 data sets, 1,934 samples) and Standard Q nasal (sensitivity of

83.8% (95% CI 77.8 to 88.4); 5 data sets, 683 samples). Specificity was above 98.6% for all tests.

In contrast, when the Panbio (14 data sets, 9,233 samples) and Standard Q (14 data sets, 4,714

samples) tests were not performed according to IFU, pooled sensitivity decreased to 64.3% (95% CI

50.9 to 75.8) and 67.4 (95% CI 57.2 to 76.2), respectively.

Subgroup analysis by sample type

Most data sets evaluated NP or combined NP/OP swabs (122 data sets and 59,810 samples) as

the sample type for the Ag-RDT. NP or combined NP/OP swabs achieved a pooled sensitivity of 71.6%

(95% CI 68.1 to 74.9). Data sets that used AN/MT swabs for Ag-RDTs (32 data sets and 25,814 sam-

ples) showed a summary estimate for sensitivity of 75.5% (95% CI 70.4 to 79.9). This was confirmed

by two studies that reported direct head-to-head comparison of NP and MT samples from the same

participants using the same Ag-RDT (Standard Q), where the two sample types showed equivalent

performance [271,272]. Analysis of performance with an OP swab (seven data sets, 5,165 samples),

showed pooled sensitivity of only 53.1% (95%CI 40.9 to 65.0). Saliva swabs (four data sets, 1,088

samples) showed the lowest pooled sensitivity with only 37.9% (95% CI 11.8 to 73.5) (Fig 4C).

We were not able to perform a subgroup meta-analysis for BAL/TW due to insufficient data as

there was only one study with 73 samples evaluating the Rapigen, Panbio and Standard Q [286].

However, BAL/TW would in any case be considered an off-label use.

Subgroup analysis in symptomatic and asymptomatic patients

Within the data sets possible to meta-analyze, 17,964 (54.1%) samples were from symptomatic

and 15,228 (45.9%) from asymptomatic patients. The pooled sensitivity for symptomatic patients was

markedly different compared to asymptomatic patients with 76.7% (95% CI 70.6 to 81.9) vs. 52.5%

(95% CI 43.7 to 61.1). Specificity was 99% for both groups (Figu 4D). Median Ct-values differed in

symptomatic and asymptomatic patients. For those studies where it was possible to extract a median

Ct-value, it ranged from 20.5 to 27.0 in symptomatic [170,207,226,258,271,272] and from 27.2 to

30.5 in asymptomatic [170,201,258] patients.

Subgroup analysis comparing symptom duration

Data were analyzed for 5,538 patients with symptoms less than 7 days, but very limited data

were available for patients with symptoms ≥ 7 days (397 patients). The pooled sensitivity for patients

with onset of symptoms <7 days was 83.8% (95% CI 76.3 to 89.2) which is markedly higher than the

61.5% (95% CI 52.2 to 70.0) sensitivity for individuals tested ≥ 7 days from onset of symptoms (Fig

4D).

Subgroup analysis by age

For adult patients, it was possible to pool estimates across 3,837 samples, whereas the pediatric

group included 7,326 samples. Sensitivity and specificity were 64.3% (95% CI 54.7 to 72.9) and 99.4%

(95% CI 98.9 to 99.7) in mostly symptomatic patients <18 years. In patients ≥18, sensitivity increased

to 74.8% (95% CI 66.5 to 81.6), while the specificity was similar (98.7%, 95% CI 97.2 to 99.4) (Fig 4E).

Subgroup analysis by type of RT-PCR and viral load

We were not able to perform a meta-analysis for the subgroups by type of RT-PCR or viral load

(viral copies/mL) due to insufficient data.

In 152 (71.0%) of the data sets only one type of RT-PCR was used, whereas 37 (17.3%) tested

samples in the same data set using different RT-PCRs. For 25 (11.7%) of the data sets the type of RT-

PCR was not reported. The Cobas® SARS-CoV-2 Test from Roche (Germany) was used most frequently

in 63 (29.4%) of the data sets, followed by the Allplex® 2019 n-CoV Assay from Seegene in 41 (19.2%)

and the SARS CoV-2 assay from TaqPath in 20 (9.3%) of the data sets

Median sensitivity in samples with viral load of >5 log 10 copies/ml was 72.4% (range 46.9 to

100), 97.8% (range 71.4 to 100) for >6 log 10 copies/ml and 100% (range 93.8 to 100) for >7 log 10

copies/ml, showing that the sensitivity increases with increasing viral load.

Meta regression

We were not able to perform a meta-regression due to the considerable heterogeneity in re-

porting sub-groups, which resulted in too few studies with sufficient data for comparison.

Publication Bias

The result of the Deeks' test (p=0.001) shows significant asymmetry in the funnel plot for all datasets

with complete results. This indicates there may be publication bias from studies with small sample

sizes. However, when looking at publications specifically for LumiraDx (p=0.567), Standard Q

(p=0.23), and Panbio (p=0.35), the results do not show significant asymmetry in the funnel plots,

indicating these tests may have less publication bias. All funnel plots are listed in the Supplement

(S12).

COMPARISON WITH ANALYTICAL STUDIES

The nine analytical studies were divided into 63 data sets, evaluating 23 different Ag-RDTs. Only

seven studies reported a samples size, wherein 833 (90.6%) samples originated from NP swabs and

for 86 (9.4%) the sample type was unclear. One of the two studies not reporting sample size used

saliva samples [198], while the other used the sample type specified in the respective Ag-RDT's IFU

[173].

Overall, the reported analytical sensitivity (limit of detection) in the studies resembled the re-

sults of the meta-analysis presented above. Rapigen (limit of detection (LOD) in log10 copies per

swab: 10.2) and Coris (LOD 7.46) were found to perform worse than Panbio (LOD 6.6 to 6.1) and

Standard Q (LOD 6.8 to 6.0), whereas the Clinitest (LOD 6.0) and the BinaxNOW by Abbott (LOD 4.6

to 4.9) performed even better [191,256,282]. Similar results were found in another study, where the

Standard Q showed the lowest LOD (detecting virus up to what is an equivalent Ct-value of 26.3 to

28.7), when compared to that of Rapigen and Coris (detecting virus up to what is an equivalent Ct-

value of only 18.4 for both) [208,274,275]. However, another study found the Panbio, Standard Q,

Coris and BinaxNOW to have a similar LOD of $5.0*10^3$ plaque forming units (pfu) /milliliter (ml), but

the ESPLINE SARS-CoV-2 by Fujirebio (Japan), the COVID-19 Rapid Antigen Test by MOLOGIC (United

Kingdom) and the Sure Status COVID-19 Antigen Card Test by Premier Medical Corporation (India) to

perform markedly better (LOD 2.5 to $5.0*10^2$ pfu/ml) [173]. An overview of all LODs reported in the

studies can be found in the Supplement (S13)

SENSITIVITY ANALYSIS

When the data sets from case control studies (25/173) were excluded, the estimated sensitivity

did not differ greatly, with a value of 70.9% (95% CI 67.7 to 73.9) compared to 71.2% (95% CI 68.2 to

74.0) in the overall analysis with no change in pooled specificity. When excluding the data sets from

pre-prints (64/173), sensitivity decreased slightly to 67.2% (95% CI 62.9 to 71.3) compared to the

overall analysis.

DISCUSSION

In this comprehensive systematic review and meta-analysis, we have summarized the data of

133 studies evaluating the accuracy of 61 different Ag-RDTs. Across all meta-analyzed samples, our

results show a pooled sensitivity and specificity of 71.2% (95% CI 68.2 to 74.0) and 98.9% (95% CI

98.6 to 99.1). Over half of the studies did not perform the Ag-RDT in accordance with the test manu-

facturers' recommendation or the performance was unknown, which negatively impacted the sensi-

tivity. When considering only IFU-conforming studies, the sensitivity increased to 76.3% (95% CI 73.1

to 79.2). While we found the sensitivity to vary across specific tests, the specificity was consistently

high.

The two Ag-RDTs that have been approved through the WHO emergency use listing procedure,

Abbott Panbio and SD Biosensor Standard Q (distributed by Roche in Europe), have not only drawn

the largest research interest, but also perform at or above average when comparing their pooled

accuracy to that of all Ag-RDTs (sensitivity of 71.8% for Panbio and of 74.9% for Standard Q). The

Standard Q nasal demonstrated an even higher pooled sensitivity (80.2% compared to the NP test),

although this is likely due to variability in populations tested, as head-to-head performance showed a

comparable sensitivity. Three other Ag-RDTs showed an even higher accuracy with sensitivities rang-

ing from 77.4% to 88.2% (namely Sofia, Lumipulse G and LumiraDX), but were only assessed on rela-

tively small samples sizes (ranging from 1,373 to 3,532) and all required an instrument/reader.

Not surprisingly, lower Ct-values, the RT-PCR semi-quantitative correlate for a high virus con-

centration, resulted in a significantly higher Ag-RDT sensitivity than higher Ct-values (pooled sensitivi-

ty 96.5% and 95.8% for ct-values <20 and <25 vs. 50.7% and 20.9% for ct-values ≥25 and ≥30). This

confirms prior data that suggested that antigen concentrations and Ct-values were highly correlated

in NP samples [16]. Ag-RDTs also showed a higher sensitivity in patients within 7 days after symptom

onset compared to patients later in the course of the disease (pooled sensitivity 83.8% vs. 61.5%),

which is to be expected given that samples from patients within the first week after symptom onset

have been shown to contain the highest virus concentrations [297]. In line with this, studies reporting

an unexpectedly low overall sensitivity either shared a small population size with an on average high

Ct-value [230,273,288] or performed the Ag-RDT not as per IFU, e.g., using saliva or prediluted sam-

ples [167,170,203,248,279]. In contrast, studies with an unusually high Ag-RDT sensitivity were based

on study populations with a low median Ct-value, between 18 and 22 [189,255,284].

Our analysis also found that the accuracy of Ag-RDTs is substantially higher in symptomatic pa-

tients than in asymptomatic (pooled sensitivity 76.7% vs. 52.5%). This is not surprising as studies that

enrolled symptomatic patients showed a lower range of median Ct-values (i.e., higher viral load),

than studies enrolling asymptomatic patients. Given that other studies found symptomatic and

asymptomatic patients to have comparable viral loads [298,299], the differences found in our analy-

sis are likely explained by the varied time in the course of the disease at which testing is performed in

asymptomatic patients presenting for one-time screening testing. As symptoms start in the early

phase of the disease when viral load is still high, studies testing only symptomatic patients have a

higher chance of including patients with high viral loads. In contrast, study populations drawn from

asymptomatic patients only have a higher chance of including patients at any point of disease (i.e.,

including late in disease, when PCR is still positive, but viable virus is rapidly decreasing) [300].

With regards to the sampling and testing procedure, we found Ag-RDTs to perform similarly

across upper-respiratory swab samples (e.g., NP and AN/MT), particularly when considering the most

reliable comparisons from head-to-head studies.

Similar to previous assessment [7], the methodological quality of the included studies revealed a

very heterogenous picture. In the future, aligning the design of clinical accuracy studies to common

agreed upon minimal specifications (e.g., by WHO or European Center of Disease Control) and re-

porting the results in a standardized way [301] would improve data quality and comparability.

The main strengths of our study lie in its comprehensive approach and continuous updates. By

linking this review to our website www.diagnosticsglobalhealth.org, we strive to equip decision mak-

ers with the latest research findings on Ag-RDTs for SARS-CoV-2 and, to the best of our knowledge,

are the first in doing so. At least once per week the website is updated by continuing the literature

search and process described above. We plan to update the meta-analysis on a monthly basis and

publish it on the website. Furthermore, our study used rigorous methods as both the study selection

and data extraction were performed by one author and independently validated by a second, we

conducted blinded pilot extractions before of the actual data extraction, and we prepared a detailed

interpretation guide for the QUADAS-2 tool.

The study may be limited by the inclusion of both preprints and peer-reviewed literature, which

could affect the quality of the data extracted. However, we aimed to balance this potential effect by

applying a thorough assessment of all clinical studies included, utilizing the QUADAS-2 tool and per-

forming a sensitivity analysis excluding preprint manuscripts. In addition, the studies included in our

analysis varied widely in the reported range of viral loads, limiting the comparability of their results.

To control for this, we analyzed the Ag-RDTs' performance at different levels of viral load. Finally,

even though we are aware that further data exits from other sources, for example from governmen-

tal research institutes exists [302], such data could not be included as sufficient detail describing the

methods and results are not publicly available.

CONCLUSION

In summary, it can be concluded that there are Ag-RDTs available that have high sensitivity, par-

ticularly when performed in the first week of illness when viral load is high, and excellent specificity.

However, our analysis also highlights the variability in results between tests (which is not reflected in

the manufacturer reported data), indicating the need for independent validations. Furthermore, the

analysis highlights the importance of performing tests in accordance with the manufacturers' rec-

ommended procedures, and in alignment with standard diagnostic evaluation and reporting guide-

lines. The accuracy achievable by the best-performing Ag-RDTs, combined with the rapid turn-around

time compared to RT-PCR, suggests that these tests could have a significant impact on the pandemic

if applied in thoughtful testing and screening strategies.

SOURCES

1.   World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using
rapid immunoassays: interim guid-ance, 11 September 2020. No WHO/2019-
nCoV/Antigen_Detection/20201, 2020b.
2.   Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for
Containment. New England Journal of Medicine, 2020; 383(22). DOI:10.1056/NEJMp2025631.
3.   Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und
Medizinprodukte). Liste der Antigen-Tests zum direkten Erregernachweis des Coronavirus SARS-CoV-
2 2021 [Available from: https://www.bfarm.de/DE/Medizinprodukte/Antigentests/_node.html,
accessed on June 07, 2021.
4.   Krüger LJ, Gaeddert M, Köppel L, Brümmer LE, Gottschalk C, Miranda IB, et al. Evaluation of
the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care
diagnostics for SARS-CoV-2. medRxiv [Preprint]; published October 04, 2020.
DOI:10.1101/2020.10.01.20203836.
5.   Denkinger CM, Grenier J, Minion J, Pai M. Promise versus reality: optimism bias in package
inserts for tuberculosis diagnostics. Journal of Clinical Microbiology, 2012; 50(7):2455-61.
DOI:10.1128/JCM.00842-12.
6.   World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for
COVID-19: scientific brief, 8 April 2020. No WHO/2019-
nCoV/Sci_Brief/POC_immunodiagnostics/20201, 2020a.
7.   Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, et al. Rapid, point-of-care
antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection (Review). Cochrane
Database of Systematic Reviews, 2020; (8). DOI:10.1002/14651858.Cd013705.
8.   Olalekan A, Iwalokun B, Akinloye OM, Popoola O, Samuel TA, Akinloye O. COVID-19 rapid
diagnostic test could contain transmission in low- And middle-income countries. African Journal of
Laboratory Medicine, 2020; 9(1). DOI:10.4102/ajlm.v9i1.1255.
9.   Castro R, Luz PM, Wakimoto MD, Veloso VG, Grinsztejn B, Perazzo H. COVID-19: a meta-
analysis of diagnostic test accuracy of commercial assays registered in Brazil. Brazilian Journal of
Infectious Diseases, 2020; 24(2):180-187. DOI:10.1016/j.bjid.2020.04.003.
10.   La Marca A, Capuzzo M, Paglia T, Roli L, Trenti T, Nelson SM. Testing for SARS-CoV-2 (COVID-
19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays.
Reproductive Biomedicine Online, 2020; 41(3):483-499. DOI:10.1016/j.rbmo.2020.06.001.
11.   Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al. Rapid, point-of-care
antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database of
Systematic Reviews, 2021; 3:CD013705. DOI:10.1002/14651858.CD013705.pub2.
12.   Van Walle I, Leitmeyer K, Broberg E. Meta-analysis of the clinical performance of commercial
SARS-CoV-2 nucleic acid, antigen and antibody tests up to 22 August 2020. medRxiv [Preprint];
published September 18, 2020, 2020. DOI:10.1101/2020.09.16.20195917.
13.   Hayer J, Kasapic D, Zemmrich C. Real-world clinical performance of commercial SARS-CoV-2
rapid antigen tests in suspected COVID-19: A systematic meta-analysis of available data as per
November 20, 2020. medRxiv [Preprint]; published December 24, 2020.
DOI:10.1101/2020.12.22.20248614.
14.   Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM, Cochrane Diagnostic Test Accuracy Working
G. Systematic reviews of diagnostic test accuracy. Annals of Internal Medicine, 2008; 149(12):889-97.
DOI:10.7326/0003-4819-149-12-200812160-00008.
15.   Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic
reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine, 2009; 151(4):264-9,
W64. DOI:10.7326/0003-4819-151-4-200908180-00135.
16.   Pollock N, Savage T, Wardell H, Lee R, Mathew A, Stengelin M, et al. Correlation of SARS-CoV-
2 nucleocapsid antigen and RNA concentrations in nasopharyngeal samples from children and adults

using an ultrasensitive and quantitative antigen assay. medRxiv [Preprint]; published November 13,
2020. DOI:10.1101/2020.11.10.20227371.

17.   Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a
revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine,
2011; 155(8):529-36. DOI:10.7326/0003-4819-155-8-201110180-00009.

18.   van Enst WA, Ochodo E, Scholten RJ, Hooft L, Leeflang MM. Investigation of publication bias
in meta-analyses of diagnostic test accuracy: a meta-epidemiological study. BMC Med Research
Methodology, 2014; 14:70. DOI:10.1186/1471-2288-14-70.

19.   Courtellemont L, Guinard J, Guillaume C, Giaché S, Rzepecki V, Seve A, et al. Real-life
performance of a novel antigen detection test on nasopharyngeal specimens for SARS-CoV-2
infection diagnosis: a prospective study. medRxiv [Preprint]; published November 3, 2020.
DOI:10.1101/2020.10.28.20220657.

20.   Diao B, Wen K, Chen J, Liu Y, Yuan Z, Han C, et al. Diagnosis of Acute Respiratory Syndrome
Coronavirus 2 Infection by Detection of Nucleocapsid Protein. medRxiv [Preprint]; published March
13, 2020. DOI:10.1101/2020.03.07.20032524.

21.   Foundation for Innovative New Diagnostics. FIND Evaluation of Abbott Panbio COVID-19 Ag
Rapid Test Device. External Report Version 21, 10 December, 2020.

22.   Foundation for Innovative New Diagnostics. FIND Evaluation of Coris BioConcept COVID-19
Ag Respi-Strip. External Report Version 12, 10 December, 2020.

23.   Foundation for Innovative New Diagnostics. FIND Evaluation of Shenzhen Bioeasy
Biotechnology Co. Ltd. 2019-nCoV Ag Rapid Test Kit (Fluorescence). External Report Version 10, 11
February 2021, 2021.

24.   Ikeda M, Imai K, Tabata S, Miyoshi K, Mizuno T, Murahara N, et al. Clinical evaluation of self-
collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid antigen test to diagnose COVID-
19. medRxiv [Preprint]; published June 08, 2020. DOI:10.1101/2020.06.06.20124123.

25.   Klein JAF, Krüger L, Tobian F, Gaeddert M, Lainati F, Schnitzler P, et al. Head-to-head
performance comparison of self-collected nasal versus professional-collected nasopharyngeal swab
for a WHO-listed SARS-CoV-2 antigen-detecting rapid diagnostic test. medRxiv [Preprint]; published
March 24, 2021. DOI:10.1101/2021.03.17.21253076.

26.   Masiá M, Fernández-González M, Sánchez M, Carvajal M, García JA, Gonzalo N, et al.
Nasopharyngeal Panbio COVID-19 antigen performed at point-of-care has a high sensitivity in
symptomatic and asymptomatic patients with higher risk for transmission and older age. medRxiv
[Preprint]; published November 17, 2020. DOI:10.1101/2020.11.16.20230003.

27.   Weitzel T, Legarraga P, Iruretagoyena M, Pizarro G, Vollrath V, Araos R, et al. Head-to-head
comparison of four antigen-based rapid detection tests for the diagnosis of SARS-CoV-2 in respiratory
samples. bioRxiv [Preprint]; published May 30, 2020. DOI:10.1101/2020.05.27.119255.

28.   Peeling RW, Olliaro P. Rolling out COVID-19 antigen rapid diagnostic tests: the time is now.
Lancet Infectious Diseases, 2021; online first. DOI:10.1016/s1473-3099(21)00152-3.

29.   Cui Z, Chang H, Wang H, Lim B, Hsu CC, Yu Y, et al. Development of a rapid test kit for SARS-
CoV-2: an example of product design. Bio-Design and Manufacturing, 2020:1-4. DOI:10.1007/s42242-
020-00075-7.

30.   Ndwandwe D, Mathebula L, Kamadjeu R, Wiysonge CS. Cochrane corner: rapid point-of-care
antigen and molecular-based tests for the diagnosis of COVID-19 infection. The Pan African Medical
Journal, 2020; 37(Suppl 1):10. DOI:10.11604/pamj.supp.2020.37.10.25982.

31.   Pavelka M, Van-Zandvoort K, Abbott S, Sherratt K, Majdan M, Jarčuška P, et al. The
effectiveness of population-wide, rapid antigen test based screening in reducing SARS-CoV-2
infection prevalence in Slovakia. medRxiv [Preprint]; published December 04,, 2020.
DOI:10.1101/2020.12.02.20240648.

32.   Ebrahimi M, Harmooshi NN, Rahim F. Diagnostic Utility of Antigen Detection Rapid Diagnostic
Tests for Covid- 19: A Systematic Review and Meta-Analysis. medRxiv [Preprint]; published April 05,
2021. DOI:10.1101/2021.04.02.21254714.

33.   Everitt ML, Tillery A, David MG, Singh N, Borison A, White IM. A critical review of point-of-
care diagnostic technologies to combat viral pandemics. Analytica Chimica Acta, 2021; 1146:184-199.
DOI:10.1016/j.aca.2020.10.009.
34.   Hledík M, Polechová J, Beiglböck M, Herdina AN, Strassl R, Posch M. Analysis of the specificity
of the SD Biosensor Standard Q Ag-Test based on Slovak mass testing data. medRxiv [Preprint];
published December 11, 2020. DOI:10.1101/2020.12.08.20246090.
35.   Huergo MAC, Thanh NTK. Current advances in the detection of COVID-19 and evaluation of
the humoral response. Analyst, 2021; 146:382-402. DOI:10.1039/d0an01686a.
36.   Laghrib F, Saqrane S, El Bouabi Y, Farahi A, Bakasse M, Lahrich S, et al. Current progress on
COVID-19 related to biosensing technologies: New opportunity for detection and monitoring of
viruses. Microchemical Journal, 2021; 160:105606. DOI:10.1016/j.microc.2020.105606.
37.   Maddali H, Miles CE, Kohn J, O'Carroll DM. Optical Biosensors for Virus Detection: Prospects
for SARS-CoV-2/COVID-19. Chembiochem, 2021; 22(7):1176-1189. DOI:10.1002/cbic.202000744.
38.   Marchán-López Á, García BA. Diagnostic performance of antigen testing for SARS-CoV-2. The
Journal of Pediatrics, 2021; 233:283. DOI:10.1016/j.jpeds.2021.02.052.
39.   McDermott JH, Stoddard D, Ellingford JM, Gokhale D, Reynard C, Black G, et al. Utilizing
point-of-care diagnostics to minimize nosocomial infection in the 2019 novel coronavirus (SARS-CoV-
2) pandemic. QJM: An International Journal of Medicine, 2020; 113(12):851-853.
DOI:10.1093/qjmed/hcaa185.
40.   Moreira V, Mascarenhas P, Machado V, Botelho J, Mendes JJ, Taveira N, et al. Diagnosis of
SARS-Cov-2 infection using specimens other than naso- and oropharyngeal swabs: a systematic
review and meta-analysis. Diagnostics, 2021; 11:363. DOI:10.1101/2021.01.19.21250094.
41.   Nimmo C, Agbetile J, Bhowmik A, Capocci S, Rajakulasingam RK. Implementing rapid
diagnostics for COVID-19. The Lancet Respiratory Medicine, 2021; 9(1):e7. DOI:10.1016/s2213-
2600(20)30526-9.
42.   Raimann FJ, Piekarski F, Adam EH, Zacharowski K, Neef V. Safety considerations for the use of
Point-Of-Care diagnostics during SARS-CoV-2 pandemic. Journal of Clinical Laboratory Analysis, 2021;
35(1):e23631. DOI:10.1002/jcla.23631.
43.   Razmy AM, Junaideen SM. Issues of Random Sampling with Rapid Antigen Tests for COVID-19
Diagnosis: A Special Reference to Kalmunai RDHS Division. medRxiv [Preprint]; published January 20,
2021. DOI:10.1101/2021.01.11.21249636.
44.   Salcedo N, Harmon A, Herrera BB. Pooling of samples for SARS-CoV-2 detection using rapid
antigen tests. medRxiv [Preprint]; published February 12, 2021. DOI:10.1101/2021.02.09.21250610.
45.   Sanderlin JS, Golding JD, Wilcox T, Mason DH, McKelvey KS, Pearson DE, et al. Occupancy
modeling and resampling overcomes low test sensitivity to produce accurate SARS-CoV-2 prevalence
estimates. BMC Public Health, 2021; 21(1):577. DOI:10.1186/s12889-021-10609-y.
46.   Scheier T, Schibli A, Eich G, Rüegg C, Kube F, Schmid A, et al. Universal Admission Screening
for SARS-CoV-2 Infections among Hospitalized Patients, Switzerland, 2020. Emerging Infectious
Diseases, 2021; 27(2). DOI:10.3201/eid2702.202318.
47.   Stovitz SD. In suspected SARS-CoV-2, rapid antigen detection tests had 67% to 73% sensitivity
and 98% to 100% specificity. Annals of Internal Medicine, 2021; 174:JC56.
DOI:10.7326/acpj202105180-056.
48.   van Beek J, Igloi Z, Boelsums T, Fanoy E, Gotz H, Molenkamp R, et al. From more testing to
smart testing: data-guided SARS-CoV-2 testing choices. medRxiv [Preprint]; published October 14,
2020. DOI:10.1101/2020.10.13.20211524.
49.   Weiss G, Bellmann-Weiler R. Rapid antigen testing and non-infectious shedding of SARS-
Cov2. Infection, 2021; epub ahead of print. DOI:10.1007/s15010-020-01570-w.
50.   Ehrenberg A, Moehle E, Brook C, Doudna Cate A, Witkowsky L, Sachdeva R, et al. Launching a
saliva-based SARS-CoV-2 surveillance testing program on a university campus. medRxiv [Preprint];
published January 30, 2021. DOI:10.1101/2021.01.24.21250385.

51.   Boďová K, Kollár R. Characteristic spatial scales of SARS-CoV-2 pandemics: lessons from mass
rapid antigen testing in Slovakia. medRxiv [Preprint]; published December 24, 2020.
DOI:10.1101/2020.12.23.20248808.
52.   Canadian Public Health Laboratory Network. Interim guidance on the use of the Abbott
Panbio™ COVID-19 Antigen Rapid Test. Canada Communicable Disease Report, 2021; 47(1):17-22.
DOI:10.14745/ccdr.v47i01a04.
53.   Crozier A, Rajan S, Buchan I, McKee M. Put to the test: use of rapid testing technologies for
covid-19. British Medical Journal, 2021; 372:n208. DOI:10.1136/bmj.n208.
54.   D'Agostino McGowan L, Lee E, Grantz K, Kucirka L, Gurley E, Lessler J. Testing out of
quarantine. medRxiv [Preprint]; published 01, 2021. DOI:10.1101/2021.01.29.21250764.
55.   editorial. Rapid and frequent testing. Nature Biomedical Engineering, 2020; 4(12):1121-1122.
DOI:10.1038/s41551-020-00670-0.
56.   Fitzpatrick MC, Pandey A, Wells CR, Sah P, Galvani AP. Buyer beware: inflated claims of
sensitivity for rapid COVID-19 tests. Lancet, 2021; 397(10268):24-25. DOI:10.1016/s0140-
6736(20)32635-0.
57.   Frnda J, Durica M. On Pilot Massive COVID-19 Testing by Antigen Tests in Europe. Case Study:
Slovakia. Infectious Disease Reports, 2021; 13(1):45-57. DOI:10.3390/idr13010007.
58.   Ghaffari A, Meurant R, Ardakani A. COVID-19 Point-of-Care Diagnostics That Satisfy Global
Target Product Profiles. Diagnostics, 2021; 11(1). DOI:10.3390/diagnostics11010115.
59.   Ruhan A, Wang H, Wang W, Tan W. Summary of the Detection Kits for SARS-CoV-2 Approved
by the National Medical Products Administration of China and Their Application for Diagnosis of
COVID-19. Virologica Sinica, 2020; 35:699-712. DOI:10.1007/s12250-020-00331-1.
60.   Abdelrazik AM, Elshafie SM, Abdelaziz HM. Potential Use of Antigen-Based Rapid Test for
SARS-CoV-2 in Respiratory Specimens in Low-Resource Settings in Egypt for Symptomatic Patients
and High-Risk Contacts. Laboratory Medicine, 2020; 52:e46-e49. DOI:10.1093/labmed/lmaa104.
61.   Aoki K, Nagasawa T, Ishii Y, Yagi S, Okuma S, Kashiwagi K, et al. Clinical validation of
quantitative SARS-CoV-2 antigen assays to estimate SARS-CoV-2 viral loads in nasopharyngeal swabs.
Journal of Infection and Chemotherapy, 2020; 27(4):613-6. DOI:10.1016/j.jiac.2020.11.021.
62.   Bonde J, Ejegod D, Pedersen H, Smith B, Cortes D, Leding C, et al. Clinical validation of point-
of-care SARS-COV-2 BD Veritor antigen test by a single throat swab for rapid COVID-19 status on
hospital patients predominantly without overt COVID symptoms. medRxiv [Preprint]; published April
17, 2021. DOI:10.1101/2021.04.12.21255299.
63.   Boum Y, Fai KN, Nicolay B, Mboringong AB, Bebell LM, Ndifon M, et al. Performance and
operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic
and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study. Lancet
Infectious Diseases, 2021; online first. DOI:10.1016/s1473-3099(21)00132-8.
64.   Courtellemont L, Guinard J, Guillaume C, Giaché S, Rzepecki V, Seve A, et al. High
performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS-
CoV-2 infection. Journal of Medical Virology, 2021; 93(5):3152-3157. DOI:10.1002/jmv.26896.
65.   Eshghifar N, Busheri A, Shrestha R, Beqaj S. Evaluation of Analytical Performance of Seven
Rapid Antigen Detection Kits for Detection of SARS-CoV-2 Virus. International Journal of General
Medicine, 2021; 14:435-440. DOI:10.2147/ijgm.S297762.
66.   Hingrat QL, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y, et al. Detection
of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new
testing alternatives. Clinical Microbiology and Infection, 2020. DOI:10.1016/j.cmi.2020.11.025.
67.   Kobayashi R, Murai R, Asanuma K, Fujiya Y, Takahashi S. Evaluating a novel, highly sensitive,
and quantitative reagent for detecting SARS-CoV-2 antigen. Journal of Infection and Chemotherapy,
2021; 27(6):800-807. DOI:10.1016/j.jiac.2021.01.007.
68.   Kritikos A, Caruana G, Brouillet R, Miroz J-P, Samia A-M, Geraldine S, et al. Sensitivity of rapid
antigen testing and RT-PCR performed on nasopharyngeal swabs versus saliva samples in COVID-19
hospitalized patients: results of a prospective comparative trial (RESTART). medRxiv [Preprint];
published April 15, 2021. DOI:10.1101/2021.04.09.21255105.

69.   Lanser L, Bellmann-Weiler R, Öttl KW, Huber L, Griesmacher A, Theurl I, et al. Evaluating the
clinical utility and sensitivity of SARS-CoV-2 antigen testing in relation to RT-PCR Ct values. Infection,
2020:1-3. DOI:10.1007/s15010-020-01542-0.
70.   Lv Y, Ma Y, Si Y, Zhu X, Zhang L, Feng H, et al. Rapid SARS-CoV-2 antigen detection potentiates
early diagnosis of COVID-19 disease. Bioscience Trends, 2021; 15(2):93-99.
DOI:10.5582/bst.2021.01090.
71.   Miyakawa K, Funabashi R, Yamaoka Y, Jeremiah SS, Katada J, Wada A, et al. SARS-CoV-2
antigen rapid diagnostic test enhanced with silver amplification technology. medRxiv [Preprint];
published January 31, 2021. DOI:10.1101/2021.01.27.21250659.
72.   Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, et al. Clinical Evaluation
of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR,
Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To
Diagnose COVID-19. Journal of Clinical Microbiology, 2020; 58(9). DOI:10.1128/jcm.01438-20.
73.   Oh SM, Jeong H, Chang E, Choe PG, Kang CK, Park WB, et al. Clinical Application of the
Standard Q COVID-19 Ag Test for the Detection of SARS-CoV-2 Infection. Journal of Korean Medical
Science, 2021; 36(14):e101. DOI:10.3346/jkms.2021.36.e101.
74.   Peña-Rodríguez M, Viera-Segura O, García-Chagollán M, Zepeda-Nuño JS, Muñoz-Valle JF,
Mora-Mora J, et al. Performance evaluation of a lateral flow assays for nasopharyngeal antigen
detection for SARS-CoV-2 diagnosis. Journal of Clinical Laboratory Analysis, 2021; 35:e23745.
DOI:10.1002/jcla.23745.
75.   Regev-Yochay G, Kriger O, Beni S, Rubin C, Mina M, Mechnik B, et al. Real World Performance
of SARS-CoV-2 Antigen Rapid Diagnostic Tests in Various Clinical Settings. medRxiv [Preprint];
published March 05, 2021. DOI:10.1101/2021.03.02.21252400.
76.   Ren A, Sohaei D, Zacharioudakis I, Sigal G, Stengelin M, Matthew A, et al. Ultrasensitive assay
for saliva-based SARS-CoV-2 antigen detection. medRxiv [Preprint]; published February 19, 2021.
DOI:10.1101/2021.02.17.21251863.
77.   Rodrigues J, Gouveia C, Santos MA, Costa O, Côrte-Real R, Brito MJ. Comparison of
nasopharyngeal samples for SARS-CoV-2 detection in a paediatric cohort. Journal of Paediatrics and
Child Health, 2021; online ahead of print. DOI:10.1111/jpc.15405.
78.   Saeed U, Uppal SR, Piracha ZZ, Rasheed A, Aftab Z, Zaheer H, et al. Evaluation of SARS-CoV-2
antigen-based rapid diagnostic kits in Pakistan: formulation of COVID-19 national testing strategy.
Virology Journal, 2021; 18(1):34. DOI:10.1186/s12985-021-01505-3.
79.   Smith R, Gibson L, Martinez P, Ke R, Mirza A, Conte M, et al. Longitudinal assessment of
diagnostic test performance over the course of acute SARS-CoV-2 infection. medRxiv [Preprint];
published March 22, 2021. DOI:10.1101/2021.03.19.21253964.
80.   Stokes W, Berenger B, Portnoy D, Scott B, Szelewicki J, Singh T, et al. Real-World Clinical
Performance of the Abbott Panbio with Nasopharyngeal, Throat and Saliva Swabs Among
Symptomatic Individuals with COVID-19. European Journal of Clinical Microbiology & Infectious
Diseases, 2021; online ahead of print. DOI:10.1101/2021.01.02.21249138.
81.   Thommes L, Burkert FR, Öttl KW, Goldin D, Loacker L, Lanser L, et al. Comparative evaluation
of four SARS-CoV-2 antigen tests in hospitalized patients. International Journal of Infectious Diseases,
2021; 105:144–146. DOI:10.1016/j.ijid.2021.02.052.
82.   Yokota I, Sakurazawa T, Sugita J, Iwasaki S, Yasuda K, Yamashita N, et al. Performance of
qualitative and quantitative antigen tests for SARS-CoV-2 in early symptomatic patients using saliva.
medRxiv [Preprint]; published November 10, 2020. DOI:10.1101/2020.11.06.20227363.
83.   Zacharias M, Stangl V, Thüringer A, Loibner M, Wurm P, Wolfgruber S, et al. Rapid Antigen
Test for Postmortem Evaluation of SARS-CoV-2 Carriage. Emerging Infectious Diseases, 2021; 27(6).
DOI:10.3201/eid2706.210226.
84.   Apostolou T, Kyritsi M, Vontas A, Loizou K, Hadjilouka A, Speletas M, et al. Development and
performance characteristics evaluation of a new Bioelectric Recognition Assay (BERA) method for
rapid Sars-CoV-2 detection in clinical samples. Journal of Virological Methods, 2021; 293:114166.
DOI:10.1016/j.jviromet.2021.114166.

85. Arnaout R, Lee RA, Lee GR, Callahan C, Cheng A, Yen CF, et al. The Limit of Detection Matters:
The Case for Benchmarking Severe Acute Respiratory Syndrome Coronavirus 2 Testing. Clinical
Infectious Diseases, 2021; ciaa1382. DOI:10.1093/cid/ciaa1382.
86. Cheah PK, Ongkili DF, Zaharuddin FS, Hashim MI, Ho CV, Lee HG, et al. Discrepancy in
Screening Performances of Different Rapid Test Kits for SARS-CoV-2; a Letter to Editor. Archives of
Academic Emergency Medicine, 2021; 9(1):e9. DOI:10.22037/aaem.v9i1.1045.
87. Doron S, Ingalls R, Beauchamp A, Boehm J, Boucher H, Chow L, et al. Weekly SARS-CoV-2
screening of asymptomatic students and staff to guide and evaluate strategies for safer in-person
learning. medRxiv [Preprint]; published March 22, 2021. DOI:10.1101/2021.03.20.21253976.
88. Grossi E, Agnoli B, Baldini M, Illari S, Bonini R, Scagnelli G. Universal Sars-Cov-2 Screening in
Pregnant Women: Experience from the Italian Epidemic Outbreak. Acta Biomed, 2021;
92(S2):e2021001. DOI:10.23750/abm.v92iS2.11320.
89. Hicks SM, Pohl K, Neeman T, McNamara HA, Parsons KM, He JS, et al. A Dual-Antigen
Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome
Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. Journal of Infectious Diseases,
2021; 223(1):10-14. DOI:10.1093/infdis/jiaa623.
90. Kiyasu Y, Akashi Y, Sugiyama A, Takeuchi Y, Notake S, Naito A, et al. A prospective evaluation
of the analytical performance of GENECUBE® HQ SARS-CoV-2 and GENECUBE® FLU A/B. medRxiv
[Preprint]; published February 25, 2021. DOI:10.1101/2021.02.24.21252337.
91. Lagi F, Trevisan S, Piccica M, Graziani L, Basile G, Mencarini J, et al. Use of the FebriDx point-
of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection
during the second (COVID-19) wave in Italy. International Journal of Infectious Diseases, 2021; article
in press. DOI:10.1016/j.ijid.2021.04.065.
92. Latiano A, Tavano F, Panza A, Palmieri O, Niro GA, Andriulli N, et al. False Positive Results Of
IgM/IgG antibodies against antigen of the SARS-CoV-2 in sera stored before the 2020 Endemia in
Italy. International Journal of Infectious Diseases, 2020; 104:159-163. DOI:10.1016/j.ijid.2020.12.067.
93. Li J, Hu X, Wang X, Yang J, Zhang L, Deng Q, et al. A novel One-pot rapid diagnostic technology
for COVID-19. Analytica Chimica Acta, 2021; 1154:338310. DOI:10.1016/j.aca.2021.338310.
94. Marsic T, Ali Z, Tehseen M, Mahas A, Hamdan S, Mahfouz M. Vigilant: An Engineered VirD2-
Cas9 Complex for Lateral Flow Assay-Based Detection of SARS-CoV2. Nano Letters, 2021; 21(8):3596–
3603. DOI:10.1021/acs.nanolett.1c00612.
95. Schleicher T, Spenlinhauer T, Amadei M, Dasch N, Gordon J, Macleod G, et al. Development
of a Multiplexed Synthetic Control for Rapid Detection of SARS-CoV-2 and Other Respiratory
Pathogens Using a Nucleic Acid Syndromic Testing Panel. Journal of Molecular Diagnostics, 2020;
22(11):S37-S37.
96. Bello-Chavolla OY, Antonio-Villa NE, Fernández-Chirino L, Guerra E, Fermín-Martínez C,
Márquez-Salinas A, et al. Diagnostic performance and clinical implications of rapid SARS-CoV-2
antigen testing in Mexico using real-world nationwide COVID-19 registry data. medRxiv [Preprint];
published January 04, 2021. DOI:10.1101/2021.01.02.21249141.
97. Dalal A, Sonika U, Kumar M, George R, Kumar A, Srivastava S, et al. COVID-19 Rapid Antigen
Test: Role in Screening Prior to Gastrointestinal Endoscopy. Clinical Endoscopy, 2021; online ahead of
print. DOI:10.5946/ce.2020.295.
98. Downs LO, Eyre DW, O'Donnell D, Jeffery K. Home-based SARS-CoV-2 lateral flow antigen
testing in hospital workers. Journal of Infection, 2021; 82(2):282-327. DOI:10.1016/j.jinf.2021.01.008.
99. Haage VC, Moreira-Soto A, Sacks J, Corman V, Drosten C, Drexler JF. Limited specificity of
SARS-CoV-2 antigen-detecting rapid diagnostic tests at low temperatures. medRxiv [Preprint];
published February 03, 2021. DOI:10.1101/2021.02.01.21250904.
100. Hoehl S, Schenk B, Rudych O, Göttig S, Foppa I, Kohmer N, et al. At-home self-testing of
teachers with a SARS-CoV-2 rapid antigen test to reduce potential transmissions in schools. medRxiv
[Preprint]; published December 07, 2020. DOI:10.1101/2020.12.04.20243410.

101.   Marco A, Solé C, Abdo IJ, Turu E. Low sensitivity of rapid antigenic tests as a screening
method in an outbreak of SARS-CoV-2 infection in prison. Enfermedades Infecciosas y Microbiología
Clínica, 2021; online ahead of print. DOI:10.1016/j.eimc.2021.01.016.
102.   Matsuda EM, de Campos IB, de Oliveira IP, Colpas DR, Carmo A, Brígido LFM. Field evaluation
of COVID-19 antigen tests versus RNA based detection: Potential lower sensitivity compensated by
immediate results, technical simplicity and low cost. Journal of Medical Virology, 2021; 93(7):4405-
4410. DOI:10.1002/jmv.26985.
103.   Moreno G, Braun K, Pray I, Segaloff H, Lim A, Poulson K, et al. SARS-CoV-2 transmission in
intercollegiate athletics not fully mitigated with daily antigen testing. medRxiv [Preprint]; published
March 06, 2021. DOI:10.1101/2021.03.03.21252838.
104.   Yamayoshi S, Sakai-Tagawa Y, Koga M, Akasaka O, Nakachi I, Koh H, et al. Comparison of
Rapid Antigen Tests for COVID-19. Viruses-Basel, 2020; 12(12). DOI:10.3390/v12121420.
105.   Yokota I, Shane P, Teshima T. Logistic advantage of two-step screening strategy for SARS-
CoV-2 at airport quarantine. medRxiv [Preprint]; published January 26, 2021.
DOI:10.1101/2021.01.25.21250509.
106.   Häuser F, Sprinzl MF, Dreis KJ, Renzaho A, Youhanen S, Kremer WM, et al. Evaluation of a
laboratory-based high-throughput SARS-CoV-2 antigen assay for non-COVID-19 patient screening at
hospital admission. Medical Microbiology and Immunology, 2021; 201(2-3):165-171.
DOI:10.1007/s00430-021-00706-5.
107.   Colavita F, Vairo F, Meschi S, Valli MB, Lalle E, Castilletti C, et al. COVID-19 Rapid Antigen Test
as Screening Strategy at Points of Entry: Experience in Lazio Region, Central Italy, August-October
2020. Biomolecules, 2021; 11(3). DOI:10.3390/biom11030425.
108.   Kotsiou OS, Pantazopoulos I, Papagiannis D, Fradelos EC, Kanellopoulos N, Siachpazidou D, et
al. Repeated Antigen-Based Rapid Diagnostic Testing for Estimating the Coronavirus Disease 2019
Prevalence from the Perspective of the Workers' Vulnerability before and during the Lockdown.
International Journal of Environmental Research and Public Health, 2021; 18(4).
DOI:10.3390/ijerph18041638.
109.   Blairon L, Wilmet A, Beukinga I, Tre-Hardy M. Implementation of rapid SARS-CoV-2 antigenic
testing in a laboratory without access to molecular methods: Experiences of a general hospital.
Journal of Clinical Virology, 2020; 129:104472. DOI:10.1016/j.jcv.2020.104472.
110.   Kashiwagi K, Ishii Y, Aoki K, Yagi S, Maeda T, Miyazaki T, et al. Immunochromatographic test
for the detection of SARS-CoV-2 in saliva. medRxiv [Preprint]; published May 25, 2020.
DOI:10.1101/2020.05.20.20107631.
111.   Itoh K, Kawamitsu T, Osaka Y, Sato K, Suzuki Y, Kiriba C, et al. False positive results in severe
acute respiratory coronavirus 2 (SARS-CoV-2) rapid antigen tests for inpatients. Journal of Infection
and Chemotherapy, 2021; 27(7):1089-1091. DOI:10.1016/j.jiac.2021.03.011.
112.   Prince-Guerra JL, Almendares O, Nolen LD, Gunn JKL, Dale AP, Buono SA, et al. Evaluation of
Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing
Sites - Pima County, Arizona, November 3-17, 2020. Morbidity and Mortality Weekly Report, 2021;
70(3):100-105. DOI:10.15585/mmwr.mm7003e3.
113.   Aoki K, Nagasawa T, Ishii Y, Yagi S, Kashiwagi K, Miyazaki T, et al. Evaluation of clinical utility
of novel coronavirus antigen detection reagent, Espline® SARS-CoV-2. Journal of Infection and
Chemotherapy, 2021; 27(2):319-322. DOI:10.1016/j.jiac.2020.11.015.
114.   Caputo V, Bax C, Colantoni L, Peconi C, Termine A, Fabrizio C, et al. Comparative analysis of
antigen and molecular tests for the detection of Sars-CoV-2 and related variants: a study on 4266
samples. International Journal of Infectious Diseases, 2021; 21:S1201-9712.
DOI:10.1016/j.ijid.2021.04.048.
115.   Ford L, Lee C, Pray IW, Cole D, Bigouette JP, Abedi GR, et al. Epidemiologic characteristics
associated with SARS-CoV-2 antigen-based test results, rRT-PCR cycle threshold values, subgenomic
RNA, and viral culture results from university testing. Clinical Infectious Diseases, 2021; ciab303.
DOI:10.1093/cid/ciab303.

116.   Hirotsu Y, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, et al. Comparison of
automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313
nasopharyngeal swabs, including from seven serially followed patients. International Journal of
Infectious Diseases, 2020; 99:397-402. DOI:10.1016/j.ijid.2020.08.029.
117.   Ishii T, Sasaki M, Yamada K, Kato D, Osuka H, Aoki K, et al. Immunochromatography and
chemiluminescent enzyme immunoassay for COVID-19 diagnosis. Journal of Infection and
Chemotherapy, 2021; 27(6):915-918. DOI:10.1016/j.jiac.2021.02.025.
118.   Kiyasu Y, Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, et al. Prospective
analytical performance evaluation of the QuickNavi™-COVID19 Ag for asymptomatic individuals.
medRxiv [Preprint]; published April 07, 2021. DOI:10.1101/2021.04.01.21254813.
119.   Korenkov M, Poopalasingam N, Madler M, Vanshylla K, Eggeling R, Wirtz M, et al. Reliable
assessment of in vitro SARS-CoV-2 infectivity by a Rapid Antigen Detection Test. medRxiv [Preprint];
published April 06, 2021. DOI:10.1101/2021.03.30.21254624.
120.   Kronberg Jakobsen K, Schmidt Jensen J, Todsen T, Lippert F, Jean-Marie Martel C, Klokker M,
et al. Detection of SARS-CoV-2 infection by rapid antigen test in comparison with RT-PCR in a public
setting. medRxiv [Preprint]; published January 25, 2021. DOI:10.1101/2021.01.22.21250042.
121.   Kweon OJ, Lim YK, Kim HR, Choi Y, Kim MC, Choi SH, et al. Evaluation of rapid SARS-CoV-2
antigen tests, AFIAS COVID-19 Ag and ichroma COVID-19 Ag, with serial nasopharyngeal specimens
from COVID-19 patients. PLoS One, 2021; 16(4):e0249972. DOI:10.1371/journal.pone.0249972.
122.   Landaas ET, Storm ML, Tollånes MC, Barlinn R, Kran AB, Bragstad K, et al. Diagnostic
performance of a SARS-CoV-2 rapid antigen test in a large, Norwegian cohort. Journal of Clinical
Virology, 2021; 137:104789. DOI:10.1016/j.jcv.2021.104789.
123.   McAulay K, Kaleta EJ, Grys TE. Rapid Detection of SARS-CoV-2 Antigen from Serum in a
Hospitalized Population. medRxiv [Preprint]; published December 22, 2020.
DOI:10.1101/2020.12.21.20248140.
124.   McKay SL, Tobolowsky FA, Moritz ED, Hatfield KM, Bhatnagar A, LaVoie SP, et al.
Performance Evaluation of Serial SARS-CoV-2 Rapid Antigen Testing During a Nursing Home
Outbreak. Annals of Internal Medicine, 2021; online ahead of print. DOI:10.7326/m21-0422.
125.   Pray IW, Ford L, Cole D, Lee C, Bigouette JP, Abedi GR, et al. Performance of an Antigen-
Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses -
Wisconsin, September-October 2020. Morbidity and Mortality Weekly Report, 2021; 69(5152):1642-
1647. DOI:10.15585/mmwr.mm695152a3.
126.   Rastawicki W, Gierczyński R, Juszczyk G, Mitura K, Henry BM. Evaluation of PCL rapid point of
care antigen test for detection of SARS-CoV-2 in nasopharyngeal swabs. Journal of Medical Virology,
2021; 93(4):1920-1922. DOI:10.1002/jmv.26765.
127.   Shah M, Salvatore P, Ford L, Kamitani E, Whaley M, Mitchell K, et al. Performance of Repeat
BinaxNOW SARS-CoV-2 Antigen Testing in a Community Setting, Wisconsin, November-December
2020. Clinical Infectious Diseases, 2021; online ahead of print. DOI:10.1101/2021.04.05.21254834.
128.   Uwamino Y, Nagata M, Aoki W, Nakagawa T, Inose R, Yokota H, et al. Accuracy of rapid
antigen detection test for nasopharyngeal swab specimens and saliva samples in comparison with
RT-PCR and viral culture for SARS-CoV-2 detection. Journal of Infection and Chemotherapy, 2021;
27(7):1058-1062. DOI:10.1016/j.jiac.2021.04.010.
129.   Winkel BMF, Schram E, Gremmels H, Debast S, Schuurman R, Wensing AMJ, et al. Screening
for SARS-CoV-2 infection in asymptomatic individuals using the Panbio™ COVID-19 Antigen Rapid
Test (Abbott) compared to RT-qPCR. medRxiv [Preprint]; published December 04, 2020.
DOI:10.1101/2020.12.03.20243311.
130.   Yamamoto K, Suzuki M, Yamada G, Sudo T, Nomoto H, Kinoshita N, et al. Utility of the
antigen test for coronavirus disease 2019: Factors influencing the prediction of the possibility of
disease transmission. International Journal of Infectious Diseases, 2021; 104:65-72.
DOI:10.1016/j.ijid.2020.12.079.

131.   Ahava M, Kurkela S, Kuivanen S, Lappalainen M, Jarva H, Jaaskelainen A. Detection of SARS-
CoV-2 nucleocapsid antigen from serum can aid in timing of COVID-19 infection. medRxiv [Preprint];
published January 13, 2021. DOI:10.1101/2021.01.08.20248771.
132.   Azzi L, Baj A, Alberio T, Lualdi M, Veronesi G, Carcano G, et al. Rapid Salivary Test suitable for
a mass screening program to detect SARS-CoV-2: A diagnostic accuracy study. Journal of Infection,
2020; 81(3):E75-E78. DOI:10.1016/j.jinf.2020.06.042.
133.   Barauna VG, Singh MN, Barbosa LL, Marcarini WD, Vassallo PF, Mill JG, et al. Ultrarapid On-
Site Detection of SARS-CoV-2 Infection Using Simple ATR-FTIR Spectroscopy and an Analysis
Algorithm: High Sensitivity and Specificity. Analytical Chemistry, 2021; 93(5):2950–2958.
DOI:10.1021/acs.analchem.0c04608.
134.   Barlev-Gross M, Weiss S, Ben-Shmuel A, Sittner A, Eden K, Mazuz N, et al. Spike vs
nucleocapsid SARS-CoV-2 antigen detection: application in nasopharyngeal swab specimens.
Analytical and Bioanalytical Chemistry, 2021; 413:3501–3510. DOI:10.1101/2021.03.08.21253148.
135.   Cardozo KHM, Lebkuchen A, Okai GG, Schuch RA, Viana LG, Olive AN, et al. Establishing a
mass spectrometry-based system for rapid detection of SARS-CoV-2 in large clinical sample cohorts.
Nature Communications, 2020; 11(1):6201. DOI:10.1038/s41467-020-19925-0.
136.   Cazares LH, Chaerkady R, Samuel Weng SH, Boo CC, Cimbro R, Hsu HE, et al. Development of
a Parallel Reaction Monitoring Mass Spectrometry Assay for the Detection of SARS-CoV-2 Spike
Glycoprotein and Nucleoprotein. Analytical Chemistry, 2020; 92(20):13813-13821.
DOI:10.1021/acs.analchem.0c02288.
137.   Chen H, Li Z, Feng S, Wang A, Richard-Greenblatt M, Hutson E, et al. Femtomolar SARS-CoV-2
Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen
Burden Quantitation and Dynamics Tracking. medRxiv [Preprint]; published March 26, 2021.
DOI:10.1101/2021.03.17.21253847.
138.   Colavita F, Vairo F, Meschi S, Valli B, Lalle E, Castilletti C, et al. COVID-19 Antigen Rapid Test
as Screening Strategy at the Points-of-Entry: Experience in Lazio Region, Central Italy, August-October
2020. medRxiv [Preprint]; published November 30, 2020. DOI:10.1101/2020.11.26.20232728.
139.   Conzelmann C, Gilg A, Groß R, Schütz D, Preising N, Ständker L, et al. An enzyme-based
immunodetection assay to quantify SARS-CoV-2 infection. Antiviral Research, 2020; 181:104882.
DOI:10.1016/j.antiviral.2020.104882.
140.   Di Domenico M, De Rosa A, Boccellino M. Detection of SARS-COV-2 Proteins Using an ELISA
Test. Diagnostics (Basel), 2021; 11(4). DOI:10.3390/diagnostics11040698.
141.   Diao B, Wen K, Zhang J, Chen J, Han C, Chen Y, et al. Accuracy of a nucleocapsid protein
antigen rapid test in the diagnosis of SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020;
27(2):289.e1-289.e4. DOI:10.1016/j.cmi.2020.09.057.
142.   Ducrest PJ. Development and Evaluation of a new Swiss Made SARS-CoV-2 antigen-detecting
rapid test. medRxiv [Preprint]; published March 26, 2021. DOI:10.1101/2021.03.25.21252280.
143.   Grant BD, Anderson CE, Williford JR, Alonzo LF, Glukhova VA, Boyle DS, et al. SARS-CoV-2
Coronavirus Nucleocapsid Antigen-Detecting Half-Strip Lateral Flow Assay Toward the Development
of Point of Care Tests Using Commercially Available Reagents. Analytical Chemistry, 2020;
92(16):11305-11309. DOI:10.1021/acs.analchem.0c01975.
144.   Huang L, Ding L, Zhou J, Chen S, Chen F, Zhao C, et al. One-step rapid quantification of SARS-
CoV-2 virus particles via low-cost nanoplasmonic sensors in generic microplate reader and point-of-
care device. Biosensors and Bioelectronics, 2021; 171:112685. DOI:10.1016/j.bios.2020.112685.
145.   Kyosei Y, Namba M, Yamura S, Takeuchi R, Aoki N, Nakaishi K, et al. Proposal of De Novo
Antigen Test for COVID-19: Ultrasensitive Detection of Spike Proteins of SARS-CoV-2. Diagnostics,
2020; 10(8). DOI:10.3390/diagnostics10080594.
146.   Lee JH, Choi M, Jung Y, Lee SK, Lee CS, Kim J, et al. A novel rapid detection for SARS-CoV-2
spike 1 antigens using human angiotensin converting enzyme 2 (ACE2). Biosensors and
Bioelectronics, 2021; 171:112715. DOI:10.1016/j.bios.2020.112715.

147.   Lee L, Liu F, Chen Y, Roma G. Quantitative and Ultrasensitive In-situ Immunoassay Technology
for SARS-CoV-2 Detection in Saliva. Research Square [Preprint]; published January 18, 2021.
DOI:10.21203/rs.3.rs-138025/v1.
148.   Li Y, Peng Z, Holl NJ, Hassan MR, Pappas JM, Wei C, et al. MXene-Graphene Field-Effect
Transistor Sensing of Influenza Virus and SARS-CoV-2. ACS Omega, 2021; 6(10):6643-6653.
DOI:10.1021/acsomega.0c05421.
149.   Liu D, Ju C, Han C, Shi R, Chen X, Duan D, et al. Ultra-sensitive nanozyme-based
chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection. bioRxiv [Preprint];
published June 05, 2020. DOI:10.1101/2020.06.05.131748.
150.   Mahari S, Roberts A, Shahdeo D, Gandhi S. eCovSens-Ultrasensitive Novel In-House Built
Printed Circuit Board Based Electrochemical Device for Rapid Detection of nCovid-19. bioRxiv
[Preprint]; published May 11, 2020. DOI:10.1101/2020.04.24.059204.
151.   Nash B, Badea A, Reddy A, Bosch M, Salcedo N, Gomez AR, et al. The impact of high
frequency rapid viral antigen screening on COVID-19 spread and outcomes: a validation and
modeling study. medRxiv [Preprint]; published November 04, 2020.
DOI:10.1101/2020.09.01.20184713.
152.   Renuse S, Vanderboom P, Maus A, Kemp J, Gurtner K, Madugundu A, et al. Development of
mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from
clinical specimens. medRxiv [Preprint]; published August 06, 2020.
DOI:10.1101/2020.08.05.20168948.
153.   Ricks S, Kendall E, Dowdy D, Sacks J, Schumacher S, Arinaminpathy N. Quantifying the
potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis. BMC
Medicine, 2020; 19:75. DOI:10.1101/2020.11.20.23235317.
154.   Seo G, Lee G, Kim MJ, Baek SH, Choi M, Ku KB, et al. Rapid Detection of COVID-19 Causative
Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based
Biosensor. American Chemical Society, 2020; 14(4):5135-5142. DOI:10.1021/acsnano.0c02823.
155.   Shao W, Shurin MR, Wheeler SE, He X, Star A. Rapid Detection of SARS-CoV-2 Antigens Using
High-Purity Semiconducting Single-Walled Carbon Nanotube-Based Field-Effect Transistors. ACS
Applied Materials & Interfaces, 2021; 13(8):10321–10327. DOI:10.1021/acsami.0c22589.
156.   Singh N, Ray P, Carlin A, Magallanes C, Morgan S, Laurent L, et al. Hitting the diagnostic sweet
spot: Point-of-care SARS-CoV-2 salivary antigen testing with an off-the-shelf glucometer. medRxiv
[Preprint]; published October 02, 2020. DOI:10.1101/2020.09.24.20200394.
157.   Singh P, Chakraborty R, Marwal R, Radhakrishan VS, Bhaskar AK, Vashisht H, et al. A rapid and
sensitive method to detect SARS-CoV-2 virus using targeted-mass spectrometry. Journal of Proteins
and Proteomics, 2020:1-7. DOI:10.1007/s42485-020-00044-9 10.1007/s42485-020-00044-9.
158.   Torrente-Rodríguez RM, Lukas H, Tu J, Min J, Yang Y, Xu C, et al. SARS-CoV-2 RapidPlex: A
Graphene-based Multiplexed Telemedicine Platform for Rapid and Low-Cost COVID-19 Diagnosis and
Monitoring. Matter, 2020; 3(6):1981–1998. DOI:10.1016/j.matt.2020.09.027.
159.   Vadlamani BS, Uppal T, Verma S, Misra M. Functionalized TiO2 nanotube-based
Electrochemical Biosensor for Rapid Detection of SARS-CoV-2. Sensors, 2020; 20(20):5871.
DOI:10.1101/2020.09.07.20190173.
160.   Wang H, Hogan CA, Verghese M, Solis D, Sibai M, Huang C, et al. Ultra-sensitive Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen Detection for the Diagnosis of
Coronavirus Disease 2019 (COVID-19) in Upper Respiratory Samples. Clinical Infectious Diseases,
2021; ciab063. DOI:10.1093/cid/ciab063.
161.   Yakoh A, Pimpitak U, Rengpipat S, Hirankarn N, Chailapakul O, Chaiyo S. Paper-based
electrochemical biosensor for diagnosing COVID-19: Detection of SARS-CoV-2 antibodies and antigen.
Biosensors & Bioelectronics, 2021; 176:112912. DOI:10.1016/j.bios.2020.112912.
162.   Zakashansky J, Imamura A, Salgado D, Romero Mercieca H, Aguas RFL, Lao A, et al. Detection
of the SARS-CoV-2 spike protein in saliva with Shrinky-Dink© electrodes. medRxiv [Preprint];
published November 18, 2020. DOI:10.1101/2020.11.14.20231811.

163.   Zhang CY, Zhou L, Du K, Zhang Y, Wang J, Chen LJ, et al. Foundation and Clinical Evaluation of
a New Method for Detecting SARS-CoV-2 Antigen by Fluorescent Microsphere
Immunochromatography. Frontiers in Cellular and Infection Microbiology, 2020; 10:553837.
DOI:10.3389/fcimb.2020.553837.
164.   Zou M, Su F, Zhang R, Jiang X, Xiao H, Yan X, et al. Rapid Point-of-Care Testing for SARS-CoV-2
Virus Nucleic Acid Detection by an Isothermal and Nonenzymatic Signal Amplification System
Coupled with a Lateral Flow Immunoassay Strip. Sensors and Actuators B: Chemical, 2021;
342:129899. DOI:10.1016/j.snb.2021.129899.
165.   Akingba OL, Sprong K, Hardie DR. Field performance evaluation of the PanBio rapid SARS-
CoV-2 antigen assay in an epidemic driven by 501Y.v2 (lineage B.1.351) in the Eastern Cape, South
Africa. Journal of Clinical Virology Plus, 2021; 1(1-2):100013. DOI:10.1016/j.jcvp.2021.100013.
166.   Asai N, Sakanashi D, Ohashi W, Nakamura A, Kawamoto Y, Miyazaki N, et al. Efficacy and
validity of automated quantitative chemiluminescent enzyme immunoassay for SARS-CoV-2 antigen
test from saliva specimen in the diagnosis of COVID-19. Journal of Infection and Chemotherapy,
2021; available online. DOI:10.1016/j.jiac.2021.03.021.
167.   Baro B, Rodo P, Ouchi D, Bordoy A, Saya Amaro E, Salsench S, et al. Performance
characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic
infection: a head-to-head benchmark comparison. Journal of Infection, 2021; 82(6):269-275.
DOI:10.1016/j.jinf.2021.04.009.
168.   Basso D, Aita A, Padoan A, Cosma C, Navaglia F, Moz S, et al. Salivary SARS-CoV-2 antigen
rapid detection: a prospective cohort study. Clinica Chimica Acta, 2020; 517:54-59.
DOI:10.1016/j.cca.2021.02.014.
169.   Bruzzone B, De Pace V, Caligiuri P, Ricucci V, Guarona G, Pennati BM, et al. Comparative
diagnostic performance of different rapid antigen detection tests for COVID-19 in the real-world
hospital setting. International Journal of Infectious Diseases, 2021; 107:215-218.
DOI:10.1016/j.ijid.2021.04.072.
170.   Caruana G, Croxatto A, Kampouri E, Kritikos A, Opota O, Foerster M, et al. ImplemeNting
SARS-CoV-2 Rapid antigen testing in the Emergency wArd of a Swiss univErsity hospital: the INCREASE
study. Microorganisms, 2021; 9(4):798. DOI:10.3390/microorganisms9040798.
171.   Caruana G, Lebrun L-L, Aebischer O, Opota O, Urbano L, DeRham M, et al. The dark side of
SARS-CoV-2 rapid antigen testing: screening asymptomatic patients. medRxiv [Preprint]; published
April 27, 2021. DOI:10.1101/2021.04.24.21256040.
172.   Ciotti M, Maurici M, Pieri M, Andreoni M, Bernardini S. Performance of a rapid antigen test in
the diagnosis of SARS-CoV-2 infection. Journal of Medical Virology, 2021; 93:2988–2991.
DOI:10.1002/jmv.26830.
173.   Cubas Atienzar A, Kontogianni K, Edwards T, Wooding D, Buist K, Thompson C, et al. Limit of
detection in different matrices of nineteen commercially available rapid antigen tests for the
detection of SARS-CoV-2. medRxiv [Preprint]; published March 22, 2021.
DOI:10.1101/2021.03.19.21253950.
174.   Del Vecchio C, Brancaccio G, Brazzale AR, Lavezzo E, Onelia F, Franchin E, et al. Emergence of
N antigen SARS-CoV-2 genetic variants escaping detection of antigenic tests. medRxiv [Preprint];
published March 26, 2021. DOI:10.1101/2021.03.25.21253802.
175.   Domínguez Fernández M, Peña Rodríguez MF, Lamelo Alfonsín F, Bou Arévalo G. Experience
with Panbio™ rapid antigens test device for the detection of SARS-CoV-2 in nursing homes.
Enfermedades Infecciosas y Microbiología Clínica, 2021; S0213-005X.
DOI:10.1016/j.eimc.2020.12.008.
176.   Drain PK, Ampajwala M, Chappel C, Gvozden AB, Hoppers M, Wang M, et al. A Rapid, High-
Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point
of Care: A Clinical Performance Study. Infectious Diseases and Therapy, 2021; 10(2):753–761.
DOI:10.1007/s40121-021-00413-x.

177.   Faíco-Filho KS, Finamor Júnior FE, Moreira LVL, Lins PRG, Justo AFO, Bellei N. Evaluation of
the Panbio™ COVID-19 Ag Rapid Test at an Emergency Room in a Hospital in São Paulo, Brazil.
medRxiv [Preprint]; published March 24, 2021. DOI:10.1101/2021.03.15.21253313.
178.   Favresse J, Gillot C, Oliveira M, Cadrobbi J, Elsen M, Eucher C, et al. Head-to-Head
Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2
Infection. Journal of Clinical Medicine, 2021; 10(2):265. DOI:10.3390/jcm10020265.
179.   Ferguson J, Dunn S, Best A, Mirza J, Percival B, Mayhew M, et al. Validation testing to
determine the sensitivity of lateral flow testing for asymptomatic SARS-CoV-2 detection in low
prevalence settings: Testing frequency and public health messaging is key. PLoS Biol, 2021;
19(4):e3001216. DOI:10.1371/journal.pbio.3001216.
180.   Filgueiras P, Corsini C, Almeida NBF, Assis J, Pedrosa ML, de Oliveira A, et al. COVID-19 Rapid
Antigen Test at hospital admission associated to the knowledge of individual risk factors allow
overcoming the difficulty of managing suspected patients in hospitals COVID-19 Rapid Antigen Test
facilitates the management of suspected patients on hospital admission. medRxiv [Preprint];
published January 08, 2021. DOI:10.1101/2021.01.06.21249282.
181.   Foundation for Innovative New Diagnostics. FIND Evaluation of Boditech Medical, Inc.
iChroma COVID-19 Ag Test. External Report Version 10, 23 February 2021, 2021.
182.   Foundation for Innovative New Diagnostics. FIND Evaluation of Joysbio (Tianjin)
Biotechnology Co., Ltd. SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold). External Report Version
10, 11 February 2021, 2021.
183.   Foundation for Innovative New Diagnostics. FIND Evaluation of Guangzhou Wondfo Biotech
Co., Ltd Wondfo 2019-nCoV Antigen Test (Lateral Flow Method). Public Report Version 10, 25
February 2021, 2021.
184.   Foundation for Innovative New Diagnostics. FIND Evaluation of Abbott Panbio COVID-19 Ag
Rapid Test Device (NASAL). External Report Version 10, 11 February 2021, 2021.
185.   Foundation for Innovative New Diagnostics. FIND Evaluation of Bionote, Inc. NowCheck
COVID-19 Ag Test, nasal swab. External Report Version 10, 30 March 2021, 2021.
186.   Foundation for Innovative New Diagnostics. FIND Evaluation of Fujirebio Inc. Espline SARS-
CoV-2. External Report Version 10, 29 March 2021, 2021.
187.   Foundation for Innovative New Diagnostics. FIND Evaluation of Mologic Ltd, COVID 19 RAPID
ANTIGEN TEST. External Report Version 10, 23 April 2021, 2021.
188.   Foundation for Innovative New Diagnostics. FIND Evaluation of NADAL COVID-19 Ag Rapid
Test. External Report Version 10, 26 April 2021, 2021.
189.   Gili A, Paggi R, Russo C, Cenci E, Pietrella D, Graziani A, et al. Evaluation of automated test
Lumipulse® G SARS-CoV-2 antigen assay for detection of SARS-CoV-2 nucleocapsid protein (NP) in
nasopharyngeal swabs for community and population screening. International Journal of Infectious
Diseases, 2021; 105:P391-396. DOI:10.1016/j.ijid.2021.02.098.
190.   Gomez Marti JL, Gribschaw J, McCullough M, Mallon A, Acero J, Kinzler A, et al. Differences in
detected viral loads guide use of SARS-CoV-2 antigen-detection assays towards symptomatic college
students and children. medRxiv [Preprint]; published February 01, 2021.
DOI:10.1101/2021.01.28.21250365.
191.   Haage V, Ferreira de Oliveira-Filho E, Moreira-Soto A, Kühne A, Fischer C, Sacks JA, et al.
Impaired performance of SARS-CoV-2 antigen-detecting rapid diagnostic tests at elevated and low
temperatures. Journal of Clinical Virology, 2021; 138:104796. DOI:10.1016/j.jcv.2021.104796.
192.   Halfon P, Penaranda G, Khiri H, Garcia V, Drouet H, Philibert P, et al. An optimized stepwise
algorithm combining rapid antigen and RT-qPCR for screening of COVID-19 patients. medRxiv
[Preprint]; published January 15, 2021. DOI:10.1101/2021.01.13.21249254.
193.   Hirotsu Y, Maejima M, Shibusawa M, Amemiya K, Nagakubo Y, Hosaka K, et al. Prospective
Study of 1,308 Nasopharyngeal Swabs from 1,033 Patients using the LUMIPULSE SARS-CoV-2 Antigen
Test: Comparison with RT-qPCR. International Journal of Infectious Diseases, 2021; 105:7-14.
DOI:10.1016/j.ijid.2021.02.005.

194. Homza M, Zelena H, Janosek J, Tomaskova H, Jezo E, Kloudova A, et al. Five Antigen Tests for
SARS-CoV-2: Virus Viability Matters. Viruses, 2021; 13(4). DOI:10.3390/v13040684.
195. Houston H, Gupta-Wright A, Toke-Bjolgerud E, Biggin-Lamming J, John L. Diagnostic accuracy
and utility of SARS-CoV-2 antigen lateral flow assays in medical admissions with possible COVID-19.
Journal of Hospital Infection, 2021; 110:203-205. DOI:10.1016/j.jhin.2021.01.018.
196. Jääskeläinen AE, Ahava MJ, Jokela P, Szirovicza L, Pohjala S, Vapalahti O, et al. Evaluation of
three rapid lateral flow antigen detection tests for the diagnosis of SARS-CoV-2 infection. Journal of
Clinical Virology, 2021; 137:104785. DOI:10.1101/2020.12.30.20249057.
197. James AE, Gulley T, Kothari A, Holder K, Garner K, Patil N. Performance of the BinaxNOW
COVID-19 Antigen Card test relative to the SARS-CoV-2 real-time reverse transcriptase polymerase
chain reaction assay among symptomatic and asymptomatic healthcare employees. Infection Control
and Hospital Epidemiology, 2021:1-3. DOI:10.1017/ice.2021.20.
198. Jungnick S, Hobmaier B, Mautner L, Hoyos M, Haase M, Baiker A, et al. Detection of the new
SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in five SARS-CoV-2 rapid antigen tests (RATs),
Germany, March 2021. Euro Surveillance, 2021; 26(16):2100413. DOI:10.2807/1560-
7917.Es.2021.26.16.2100413.
199. Kannian P, Lavanya C, Ravichandran K, Gita JB, Mahanathi P, Ashwini V, et al. SARS-CoV2
antigen in whole mouth fluid may be a reliable rapid detection tool. Oral Diseases, 2021; 00:1-2.
DOI:10.1111/odi.13793.
200. Kenyeres B, Ánosi N, Bányai K, Mátyus M, Orosz L, Kiss A, et al. Comparison of four PCR and
two point of care assays used in the laboratory detection of SARS-CoV-2. Journal of Virological
Methods, 2021; 293:114165. DOI:10.1016/j.jviromet.2021.114165.
201. Kernéis S, Elie C, Fourgeaud J, Choupeaux L, Delarue SM, Alby M-L, et al. Accuracy of antigen
and nucleic acid amplification testing on saliva and naopharyngeal samples for detection of SARS-
CoV-2 in ambulatory care. medRxiv [Preprint]; published April 11, 2021.
DOI:10.1101/2021.04.08.21255144.
202. Kilic A, Hiestand B, Palavecino E. Evaluation of Performance of the BD Veritor SARS-CoV-2
Chromatographic Immunoassay Test in Patients with Symptoms of COVID-19. Journal of Clinical
Microbiology, 2021; 59(5). DOI:10.1128/jcm.00260-21.
203. Kohmer N, Toptan T, Pallas C, Karaca O, Pfeiffer A, Westhaus S, et al. The Comparative
Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In
Vitro. Journal of Clinical Medicine, 2021; 10(2). DOI:10.3390/jcm10020328.
204. Krüger L, Klein JAF, Tobian F, Gaeddert M, Lainati F, Klemm S, et al. Evaluation of accuracy,
exclusivity, limit-of-detection and ease-of-use of LumiraDx™-Antigen-detecting point-of-care device
for SARS-CoV-2. medRxiv [Preprint]; published March 05, 2021. DOI:10.1101/2021.03.02.21252430.
205. L'Huillier A, Lacour M, Sadiku D, Gadiri M, De Siebenthal L, Schibler M, et al. Diagnostic
accuracy of SARS-CoV-2 rapid antigen detection testing in symptomatic and asymptomatic children in
the clinical setting. medRxiv [Preprint]; published April 20, 2021. DOI:10.1101/2021.04.15.21255577.
206. Lefever S, Indevuyst C, Cuypers L, Dewaele K, Yin N, Cotton F, et al. Comparison of the
quantitative DiaSorin Liaison antigen test to RT-PCR for the diagnosis of COVID-19 in symptomatic
and asymptomatic outpatients. Journal of Clinical Microbiology, 2021; Online ahead of print.
DOI:10.1128/jcm.00374-21.
207. Lindner A, Nikolai O, Rohardt C, Kausch F, Wintel M, Gertler M, et al. SARS-CoV-2 patient self-
testing with an antigen-detecting rapid test: a head-to-head comparison with professional testing.
medRxiv [Preprint]; published January 08, 2021. DOI:10.1101/2021.01.06.20249009.
208. Mak GCK, Lau SSY, Wong KKY, Chow NLS, Lau CS, Lam ETK, et al. Evaluation of rapid antigen
detection kit from the WHO Emergency Use List for detecting SARS-CoV-2. Journal of Clinical
Virology, 2021; 134:104712. DOI:10.1016/j.jcv.2020.104712.
209. Mboumba Bouassa RS, Veyer D, Péré H, Bélec L. Analytical performances of the point-of-care
SIENNA™ COVID-19 Antigen Rapid Test for the detection of SARS-CoV-2 nucleocapsid protein in
nasopharyngeal swabs: A prospective evaluation during the COVID-19 second wave in France.
International Journal of Infectious Diseases, 2021; 106:8-12. DOI:10.1016/j.ijid.2021.03.051.

210.   Menchinelli G, Bordi L, Marzialiotti F, Palucci I, Capobianchi M, Sberna G, et al. Lumipulse G
SARS-CoV-2 Ag Assay Evaluation for SARS-CoV-2 Antigen Detection Using 594 Nasopharyngeal Swab
Samples from Different Testing Groups. Clinical Chemistry and Laboratory Medicine, 2021; Online
ahead of print. DOI:10.1515/cclm-2021-0182.
211.   Micocci M, Buckle P, Hayward G, Allen J, Davies K, Kierkegaard P, et al. Point of Care Testing
using rapid automated Antigen Testing for SARS-COV-2 in Care Homes – an exploratory safety,
usability and diagnostic agreement evaluation. medRxiv [Preprint]; published April 26, 2021.
DOI:10.1101/2021.04.22.21255948.
212.   Möckel M, Corman VM, Stegemann MS, Hofmann J, Stein A, Jones TC, et al. SARS-CoV-2
Antigen Rapid Immunoassay for Diagnosis of COVID-19 in the Emergency Department. Biomarkers,
2021; 26(3):213-220. DOI:10.1080/1354750x.2021.1876769.
213.   Muhi S, Tayler N, Hoang T, Ballard SA, Graham M, Rojek A, et al. Multi-site assessment of
rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence
setting: A validation and implementation study. Lancet Regional Health Western Pacific, 2021;
9:100115. DOI:10.1016/j.lanwpc.2021.100115.
214.   Ngo Nsoga M-T, Kronig I, Perez Rodriguez FJ, Sattonnet-Roche P, Da Silva D, Helbling J, et al.
Diagnostic accuracy of PanbioTM rapid antigen tests on oropharyngeal swabs for detection of SARS-
CoV-2. medRxiv [Preprint]; published February 01, 2021. DOI:10.1101/2021.01.30.21250314.
215.   Nikolai O, Rohardt C, Tobian F, Junge A, Corman V, Jones T, et al. Anterior nasal versus nasal
mid-turbinate sampling for a SARS-CoV-2 antigen-detecting rapid test: does localisation or
professional collection matter? medRxiv [Preprint]; published February 16, 2021.
DOI:10.1101/2021.02.09.21251274.
216.   Nörz D, Olearo F, Perisic S, Bauer M, Riester E, Schneider T, et al. Multicenter evaluation of a
fully automated high-throughput SARS-CoV-2 antigen immunoassay. medRxiv [Preprint]; published
April 15, 2021. DOI:10.1101/2021.04.09.21255047.
217.   Okoye NC, Barker AP, Curtis K, Orlandi RR, Snavely EA, Wright C, et al. Performance
Characteristics of BinaxNOW COVID-19 Antigen Card for Screening Asymptomatic Individuals in a
University Setting. Journal of Clinical Microbiology, 2021; 59(4):e03282-20. DOI:10.1128/jcm.03282-
20.
218.   Osmanodja B, Budde K, Zickler D, Naik M, Hofmann J, Gertler M, et al. Diagnostic accuracy of
a novel SARS-CoV-2 antigen-detecting rapid diagnostic test from standardized self-collected anterior
nasal swabs. medRxiv [Preprint]; published April 23, 2021. DOI:10.1101/2021.04.20.21255797.
219.   Osterman A, Baldauf HM, Eletreby M, Wettengel JM, Afridi SQ, Fuchs T, et al. Evaluation of
two rapid antigen tests to detect SARS-CoV-2 in a hospital setting. Medical Microbiology and
Immunology, 2021; 210(1):65-72. DOI:10.1007/s00430-020-00698-8.
220.   Pena M, Ampuero M, Garces C, Gaggero A, Garcia P, Velasquez MS, et al. Performance of
SARS-CoV-2 rapid antigen test compared with real-time RT-PCR in asymptomatic individuals. medRxiv
[Preprint]; published February 13, 2021. DOI:10.1101/2021.02.12.21251643.
221.   Pérez-García F, Romanyk J, Gómez-Herruz P, Arroyo T, Pérez-Tanoira R, Linares M, et al.
Diagnostic performance of CerTest and Panbio antigen rapid diagnostic tests to diagnose SARS-CoV-2
infection. Journal of Clinical Virology, 2021; 137:104781. DOI:10.1016/j.jcv.2021.104781.
222.   Peto T, Team UC-LFO. COVID-19: Rapid Antigen detection for SARS-CoV-2 by lateral flow
assay: a national systematic evaluation for mass-testing. medRxiv [Preprint]; published January 26,
2021. DOI:10.1101/2021.01.13.21249563.
223.   Pickering S, Batra R, Snell L, Merrick B, Nebbia G, Douthwaite S, et al. Comparative
performance of SARS-CoV-2 lateral flow antigen tests demonstrates their utility for high sensitivity
detection of infectious virus in clinical specimens. medRxiv [Preprint]; published March 02, 2021.
DOI:10.1101/2021.02.27.21252427.
224.   Pollock N, Jacobs J, Tran K, Cranston A, Smith S, O'Kane C, et al. Performance and
Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-throughput Drive-
through Community Testing Site in Massachusetts. Journal of Clinical Microbiology, 2021; 59(5).
DOI:10.1101/2021.01.09.21249499.

225.   Pollock N, Tran K, Jacobs J, Cranston A, Smith S, O'Kane C, et al. Performance and Operational
Evaluation of the Access Bio CareStart Rapid Antigen Test in a High-throughput Drive-through
Community Testing Site in Massachusetts. medRxiv [Preprint]; published March 09, 2021.
DOI:10.1101/2021.03.07.21253101.
226.   Ristić M, Nikolić N, Čabarkapa V, Turkulov V, Petrović V. Validation of the STANDARD Q
COVID-19 antigen test in Vojvodina, Serbia. PLoS One, 2021; 16(2):e0247606.
DOI:10.1371/journal.pone.0247606.
227.   Rodgers M, Batra R, Snell L, Daghfal D, Roth R, Huang S, et al. Detection of SARS-CoV-2
variants by Abbott molecular, antigen, and serological tests. medRxiv [Preprint]; published April 26,
2021. DOI:10.1101/2021.04.24.21256045.
228.   Rottenstreich A, Zarbiv G, Kabiri D, Porat S, Sompolinsky Y, Reubinoff B, et al. Rapid antigen
detection testing for universal screening for severe acute respiratory syndrome coronavirus 2 in
women admitted for delivery. American Journal of Obstetrics and Gynecology, 2021; 224(5):539-540.
DOI:10.1016/j.ajog.2021.01.002.
229.   Salvagno GL, Gianfilippi G, Bragantini D, Henry BM, Lippi G. Clinical assessment of the Roche
SARS-CoV-2 rapid antigen test. Diagnosis, 2021; Ahead of print. DOI:10.1515/dx-2020-0154.
230.   Sberna G, Lalle E, Capobianchi MR, Bordi L, Amendola A. Letter of concern re:
"Immunochromatographic test for the detection of SARS-CoV-2 in saliva. J Infect Chemother. 2021
Feb;27(2):384-386. doi: 10.1016/j.jiac.2020.11.016.". Journal of Infection and Chemotherapy, 2021;
Article in press. DOI:10.1016/j.jiac.2021.04.003.
231.   Schuit E, Veldhuijzen IK, Venekamp RP, van den Bijllaardt W, Pas SD, Lodder EB, et al.
Diagnostic accuracy of rapid antigen tests in pre-/asymptomatic close contacts of individuals with a
confirmed SARS-CoV-2 infection. medRxiv [Preprint]; published March 23, 2021.
DOI:10.1101/2021.03.18.21253874.
232.   Seitz T, Schindler S, Winkelmeyer P, Zach B, Wenisch C, Zoufaly A, et al. Evaluation of rapid
antigen tests based on saliva for the detection of SARS-CoV-2. Journal of Medical Virology, 2021;
Online ahead of print. DOI:10.1002/jmv.26983.
233.   Shidlovskaya E, Kuznetsova N, Divisenko E, Nikiforova M, Siniavin A, Ogarkova D, et al. The
Value of Rapid Antigen Tests to Identify Carriers of Viable SARS-CoV-2. medRxiv [Preprint]; published
March 12, 2021. DOI:10.1101/2021.03.10.21252667.
234.   Stohr JJM, Zwart VF, Goderski G, Meijer A, Nagel-Imming RS, Kluytmans-van den Bergh MFQ,
et al. Self-testing for the detection of SARS-CoV-2 infection with rapid antigen tests. medRxiv
[Preprint]; published February 23, 2021. DOI:10.1101/2021.02.21.21252153.
235.   Stokes W, Berenger BM, Portnoy D, Scott B, Szelewicki J, Singh T, et al. Clinical performance
of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals
with COVID-19. European Journal of Clinical Microbiology & Infectious Diseases, 2021; Online ahead
of print. DOI:10.1007/s10096-021-04202-9.
236.   Strömer A, Rose R, Schäfer M, Schön F, Vollersen A, Lorentz T, et al. Performance of a Point-
of-Care Test for the Rapid Detection of SARS-CoV-2 Antigen. Microorganisms, 2020; 9(1).
DOI:10.3390/microorganisms9010058.
237.   Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, Ueda A, et al. The evaluation of a
newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: A prospective observational
study in Japan. Journal of Infection and Chemotherapy, 2021; 27(6):890-894.
DOI:10.1016/j.jiac.2021.02.029.
238.   Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, Ueda A, et al. Diagnostic
Performance and Characteristics of Anterior Nasal Collection for the SARS-CoV-2 Antigen Test: A
Prospective Study in Japan. medRxiv [Preprint]; published March 05, 2021. DOI:10.1038/s41598-021-
90026-8.
239.   Thakur P, Saxena S, Manchanda V, Rana N, Goel R, Arora R. Utility of Antigen-Based Rapid
Diagnostic Test for Detection of SARS-CoV-2 Virus in Routine Hospital Settings. Lab Med, 2021;
Online ahead of print. DOI:10.1093/labmed/lmab033.

240. Thell R, Kallab V, Weinhappel W, Mueckstein W, Heschl L, Heschl M, et al. Evaluation of a
novel, rapid antigen detection test for the diagnosis of SARS-CoV-2. medRxiv [Preprint]; published
April 22, 2021. DOI:10.1101/2021.04.22.21255637.
241. Torres I, Poujois S, Albert E, Álvarez G, Colomina J, Navarro D. Point-of-care evaluation of a
rapid antigen test (CLINITEST(Ⓡ) Rapid COVID-19 Antigen Test) for diagnosis of SARS-CoV-2 infection
in symptomatic and asymptomatic individuals. Journal of Infection, 2021; 82(5):e11–e12.
DOI:10.1016/j.jinf.2021.02.010.
242. Turcato G, Zaboli A, Pfeifer N, Ciccariello L, Sibilio S, Tezza G, et al. Clinical application of a
rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic
patients evaluated in the emergency department: a preliminary report. Journal of Infection, 2020;
82:E14-E16. DOI:10.1016/j.jinf.2020.12.012.
243. Villaverde S, Domínguez-Rodríguez S, Sabrido G, Pérez-Jorge C, Plata M, Romero MP, et al.
Diagnostic Accuracy of the Panbio SARS-CoV-2 Antigen Rapid Test Compared with Rt-Pcr Testing of
Nasopharyngeal Samples in the Pediatric Population. The Journal of Pediatrics, 2021; 232:P287-
289.E4. DOI:10.1016/j.jpeds.2021.01.027.
244. Wagenhäuser I, Knies K, Rauschenberger V, Eisenmann M, McDonogh M, Petri N, et al.
Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in
comparison to RT-qPCR. medRxiv [Preprint]; published March 29, 2021.
DOI:10.1101/2021.03.27.21253966.
245. Yin N, Debuysschere C, Decroly M, Bouazza FZ, Collot V, Martin C, et al. SARS-CoV-2
Diagnostic Tests: Algorithm and Field Evaluation From the Near Patient Testing to the Automated
Diagnostic Platform. Frontiers in Medicine, 2021; 8:380. DOI:10.3389/fmed.2021.650581.
246. Young BC, Eyre DW, Jeffery K. Use of lateral flow devices allows rapid triage of patients with
SARS-CoV-2 on admission to hospital. Journal of Infection, 2021; 82:276-316.
DOI:10.1016/j.jinf.2021.02.025.
247. Abdulrahman A, Mustafa F, AlAwadhi AI, Alansari Q, AlAlawi B, AlQahtani M. Comparison of
SARS-COV-2 nasal antigen test to nasopharyngeal RT-PCR in mildly symptomatic patients. medRxiv
[Preprint]; published December 08, 2020. DOI:10.1101/2020.11.10.20228973.
248. Agulló V, Fernández-González M, Ortiz de la Tabla V, Gonzalo-Jiménez N, García JA, Masiá M,
et al. Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs: A population-
based point-of-care study. Journal of Infection, 2020; published online ahead of issue.
DOI:10.1016/j.jinf.2020.12.007.
249. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernandez-Fuentes MA, et al. Field evaluation
of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary
healthcare centres. Clinical Microbiology and Infection, 2020; 27(3):472.e7–472.e10.
DOI:10.1016/j.cmi.2020.11.004.
250. Alemany A, Baro B, Ouchi D, Ubals M, Corbacho-Monné M, Vergara-Alert J, et al. Analytical
and Clinical Performance of the Panbio COVID-19 Antigen-Detecting Rapid Diagnostic Test. Journal of
Infection, 2020; 82(5):186-230. DOI:10.1016/j.jinf.2020.12.033.
251. Beck ET, Paar W, Fojut L, Serwe J, Jahnke RR. Comparison of Quidel Sofia SARS FIA Test to
Hologic Aptima SARS-CoV-2 TMA Test for Diagnosis of COVID-19 in Symptomatic Outpatients. Journal
of Clinical Microbiology, 2020; 59(2):e02727-20. DOI:10.1128/jcm.02727-20.
252. Berger A, Ngo Nsoga M-T, Perez Rodriguez FJ, Abi Aad Y, Sattonnet P, Gayet-Ageron A, et al.
Diagnostic accuracy of two commercial SARS-CoV-2 Antigen-detecting rapid tests at the point of care
in community-based testing centers. PLoS One, 2020; 16(3):e0248921.
DOI:10.1371/journal.pone.0248921.
253. Bulilete O, Lorente P, Leiva A, Carandell E, Oliver A, Rojo E, et al. Evaluation of the Panbio™
rapid antigen test for SARS-CoV-2 in primary health care centers and test sites. medRxiv [Preprint];
published November 16, 2020. DOI:10.1101/2020.11.13.20231316.
254. Cerutti F, Burdino E, Milia MG, Allice T, Gregori G, Bruzzone B, et al. Urgent need of rapid
tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2.
Journal of Clinical Virology, 2020; 132:104654. DOI:10.1016/j.jcv.2020.104654.

255. Chaimayo C, Kaewnaphan B, Tanlieng N, Athipanyasilp N, Sirijatuphat R, Chayakulkeeree M,
et al. Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for
laboratory diagnosis of COVID-19 in Thailand. Virology Journal, 2020; 17(1):177.
DOI:10.1186/s12985-020-01452-5.
256. Corman V, Haage V, Bleicker T, Schmidt ML, Muehlemann B, Zuchowski M, et al. Comparison
of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests. The Lancet Microbe, 2020; Online
First. DOI:10.1016/S2666-5247(21)00056-2.
257. Drevinek P, Hurych J, Kepka Z, Briksi A, Kulich M, Zajac M, et al. The sensitivity of SARS-CoV-2
antigen tests in the view of large-scale testing. medRxiv [Preprint]; published November 24, 2020.
DOI:10.1101/2020.11.23.20237198.
258. Fenollar F, Bouam A, Ballouche M, Fuster L, Prudent E, Colson P, et al. Evaluation of the
Panbio Covid-19 rapid antigen detection test device for the screening of patients with Covid-19.
Journal of Clinical Microbiology, 2020; 59:e02589-20. DOI:10.1128/JCM.02589-20.
259. Foundation for Innovative New Diagnostics. FIND Evaluation of Bionote, Inc. NowCheck
COVID-19 Ag Test. External Report Version 15, 20 April 2021, 2020.
260. Foundation for Innovative New Diagnostics. FIND Evaluation of RapiGEN Inc. BIOCREDIT
COVID-19 Ag. External Report Version 21, 10 December, 2020.
261. Foundation for Innovative New Diagnostics. FIND Evaluation of SD Biosensor, Inc.
STANDARD™ F COVID-19 Ag FIA. External Report Version 21, 10 December, 2020.
262. Foundation for Innovative New Diagnostics. FIND Evaluation of SD Biosensor, Inc. STANDARD
Q COVID-19 Ag Test. External Report Version 21, 10 December, 2020.
263. Gremmels H, Winkela BMF, Schuurmana R, Rosinghb A, Rigterc NAM, Rodriguezd O, et al.
Real-life validation of the Panbio COVID-19 Antigen Rapid Test (Abbott) in community-dwelling
subjects with symptoms of potential SARS-CoV-2 infection. EClinicalMedicine, 2020; 31:100677.
DOI:10.1016/j.eclinm.2020.100677.
264. Gupta A, Khurana S, Das R, Srigyan D, Singh A, Mittal A, et al. Rapid chromatographic
immunoassay-based evaluation of COVID-19: A cross-sectional, diagnostic test accuracy study & its
implications for COVID-19 management in India. Indian Journal of Medical Research, 2020;
153(1):126. DOI:10.4103/ijmr.IJMR_3305_20.
265. Herrera V, Hsu V, Adewale A, Hendrix T, Johnson L, Kuhlman J, et al. Testing of Healthcare
Workers Exposed to COVID19 with Rapid Antigen Detection. medRxiv [Preprint]; published August
18, 2020. DOI:10.1101/2020.08.12.20172726.
266. Igloi Z, Velzing J, van Beek J, van de Vijver D, Aron G, Ensing R, et al. Clinical evaluation of the
Roche/SD Biosensor rapid antigen test with symptomatic, non-hospitalized patients in a municipal
health service drive-through testing site. Emerging Infectious Diseases, 2020; 27(5):1323-1329.
DOI:10.3201/eid2705.204688.
267. Krüger LJ, Gaeddert M, Tobian F, Lainati F, Gottschalk C, Klein JAF, et al. Evaluation of the
accuracy and ease-of-use of Abbott PanBio - A WHO emergency use listed, rapid, antigen-detecting
point-of-care diagnostic test for SARS-CoV-2. medRxiv [Preprint]; published December 07, 2020.
DOI:10.1101/2020.11.27.20239699.
268. Krüttgen A, Cornelissen CG, Dreher M, Hornef MW, Imöhl M, Kleinesa M. Comparison of the
SARS-CoV-2 Rapid antigen test to the real star Sars-CoV-2 RT PCR kit. Journal of Virological Methods,
2020; 288:114024. DOI:10.1016/j.jviromet.2020.114024.
269. Lambert-Niclot S, Cuffel A, Le Pape S, Vauloup-Fellous C, Morand-Joubert L, Roque-Afonso
AM, et al. Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in
Nasopharyngeal Swabs. Journal of Clinical Microbiology, 2020; 58(8):e00977-20.
DOI:10.1128/jcm.00977-20.
270. Linares M, Pérez-Tanoira R, Carrero A, Romanyk J, Pérez-García F, Gómez-Herruz P, et al.
Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the
onset of symptoms. Journal of Clinical Virology, 2020; 133:104659. DOI:10.1016/j.jcv.2020.104659.

271. Lindner A, Nikolai O, Rohardt C, Burock S, Hülso C, Bölke A, et al. Head-to-head comparison of
SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal
swab. European Respiratory Journal, 2020; in press. DOI:10.1183/13993003.04430-2020.
272. Lindner AK, Nikolai O, Kausch F, Wintel M, Hommes F, Gertler M, et al. Head-to-head
comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus
professional-collected nasopharyngeal swab. European Respiratory Journal, 2021; 57(4).
DOI:10.1183/13993003.03961-2020.
273. Liotti FM, Menchinelli G, Lalle E, Palucci I, Marchetti S, Colavita F, et al. Performance of a
novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples. Clinical
Microbiology and Infection, 2020; 27:487–488. DOI:10.1016/j.cmi.2020.09.030.
274. Mak GC, Lau SS, Wong KK, Chow NL, Lau CS, Lam ET, et al. Analytical sensitivity and clinical
sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus. Journal of
Clinical Virology, 2020; 133:104684. DOI:10.1016/j.jcv.2020.104684.
275. Mak GCK, Cheng PKC, Lau SSY, Wong KKY, Lau CS, Lam ETK, et al. Evaluation of rapid antigen
test for detection of SARS-CoV-2 virus. Journal of Clinical Virology, 2020; 129:104500.
DOI:10.1016/j.jcv.2020.104500.
276. Merino-Amador P, Guinea J, Muñoz-Gallego I, González-Donapetry P, Galán J-C, Antona N, et
al. Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-Detection Test for the diagnosis of
SARS-CoV-2 infection. Clinical Microbiology and Infection, 2020; 27(5):758-761.
DOI:10.1016/j.cmi.2021.02.001.
277. Mertens P, De Vos N, Martiny D, Jassoy C, Mirazimi A, Cuypers L, et al. Development and
Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context.
Frontiers in Medicine, 2020; 7:225. DOI:10.3389/fmed.2020.00225.
278. Nalumansi A, Lutalo T, Kayiwa J, Watera C, Balinandi S, Kiconco J, et al. Field Evaluation of the
Performance of a SARS-CoV-2 Antigen Rapid Diagnostic Test in Uganda using Nasopharyngeal
Samples. International Journal of Infectious Diseases, 2020; article in press.
DOI:10.1016/j.ijid.2020.10.073.
279. Olearo F, Nörz D, Heinrich F, Sutter JP, Rödel K, Schultze A, et al. Handling and accuracy of
four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-qPCR. Journal of Clinical
Virology, 2020; 137:104782. DOI:10.1016/j.jcv.2021.104782.
280. Parada-Ricart E, Gomez-Bertomeu F, Picó-Plana E, Olona-Cabases M. Usefulness of the
antigen for diagnosing SARS-CoV-2 infection in patients with and without symptoms. Enfermedades
Infecciosas y Microbiología Clínica, 2020; S2529-993X. DOI:10.1016/j.eimc.2020.09.009.
281. Pekosz A, Cooper C, Parvu V, Li M, Andrews J, Manabe YCC, et al. Antigen-based testing but
not real-time PCR correlates with SARS-CoV-2 virus culture. Clinical Infectious Diseases, 2020;
ciaa1706. DOI:10.1093/cid/ciaa1706.
282. Perchetti GA, Huang ML, Mills MG, Jerome KR, Greninger AL. Analytical Sensitivity of the
Abbott BinaxNOW COVID-19 Ag CARD. Journal of Clinical Microbiology, 2020; accepted manuscript
posted online. DOI:10.1128/jcm.02880-20.
283. Pilarowski G, Lebel P, Sunshine S, Liu J, Crawford E, Marquez C, et al. Performance
characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San
Francisco. The Journal of Infectious Diseases, 2020; 223(7):1139-1144.
DOI:10.1101/2020.11.02.20223891.
284. Porte L, Legarraga P, Iruretagoyena M, Vollrath V, Pizarro G, Munita J, et al. Rapid SARS-CoV-
2 antigen detection by immunofluorescence – a new tool to detect infectivity. medRxiv [Preprint];
published October 06, 2020. DOI:10.1101/2020.10.04.20206466.
285. Porte L, Legarraga P, Vollrath V, Aguilera X, Munita JM, Araos R, et al. Evaluation of a novel
antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples.
International Journal of Infectious Diseases, 2020; 99:328-333. DOI:10.1016/j.ijid.2020.05.098.
286. Schildgen V, Demuth S, Lüsebrink J, Schildgen O. Limits and opportunities of SARS-CoV-2
antigen rapid tests – an experience based perspective. Pathogens, 2020; 10(38).
DOI:10.3390/pathogens10010038.

287. Schwob J-M, Miauton A, Petrovic D, Perdrix J, Senn N, Jaton K, et al. Antigen rapid tests,
nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a prospective comparative clinical trial.
medRxiv [Preprint]; published November 24, 2020. DOI:10.1101/2020.11.23.20237057.
288. Scohy A, Anantharajah A, Bodeus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H.
Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. Journal
of Clinical Virology, 2020; 129:104455. DOI:10.1016/j.jcv.2020.104455.
289. Shrestha B, Neupane A, Pant S, Shrestha A, Bastola A, Rajbhandari B, et al. Sensitivity and
specificity of lateral flow antigen test kits for covid-19 in asymptomatic population of quarantine
centre of province 3. Kathmandu University Medical Journal, 2020; 18(2):36-39.
290. Takeda Y, Mori M, Omi K. SARS-CoV-2 qRT-PCR Ct value distribution in Japan and possible
utility of rapid antigen testing kit. medRxiv [Preprint]; published June 19, 2020.
DOI:10.1101/2020.06.16.20131243.
291. Toptan T, Eckermann L, Pfeiffer A, Hoehl S, Ciesek S, Drosten C, et al. Evaluation of a SARS-
CoV-2 rapid antigen test: potential to help reduce community spread? Journal of Clinical Virology,
2020; 135:104713. DOI:10.1016/j.jcv.2020.104713.
292. Torres I, Poujois S, Albert E, Colomina J, Navarro D. Real-life evaluation of a rapid antigen test
(Panbio COVID-19 Ag Rapid Test Device) for SARS-CoV-2 detection in asymptomatic close contacts of
COVID-19 patients. Clinical Microbiology and Infection, 2020; 27(4):636.E1-636.E4.
DOI:10.1016/j.cmi.2020.12.022.
293. Van der Moeren N, Zwart V, Lodder E, Van den Bijllaardt W, Van Esch H, Stohr J, et al.
Performance evaluation of a SARS-CoV-2 rapid antigentest: test performance in the community in
the Netherlands. medRxiv [Preprint]; published October 21, 2020.
DOI:10.1101/2020.10.19.20215202.
294. Veyrenche N, Bollore K, Pisoni A, Bedin AS, Mondain AM, Ducos J, et al. Diagnosis value of
SARS-CoV-2 antigen/antibody combined testing using rapid diagnostic tests at hospital admission.
Journal of Medical Virology, 2020; 39(5):3069-3076. DOI:10.1002/jmv.26855.
295. Weitzel T, Legarraga P, Iruretagoyena M, Pizarro G, Vollrath V, Araos R, et al. Comparative
evaluation of four rapid SARS-CoV-2 antigen detection tests using universal transport medium. Travel
Medicine and Infectious Disease, 2020; 39:101942. DOI:10.1016/j.tmaid.2020.101942.
296. Young S, Taylor SN, Cammarata CL, Varnado KG, Roger-Dalbert C, Montano A, et al. Clinical
evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing
and versus the Sofia 2 SARS Antigen point-of-care test. Journal of Clinical Microbiology, 2020; 59(1).
DOI:10.1128/jcm.02338-20.
297. Kissler SM, Fauver JR, Mack C, Olesen SW, Tai C, Shiue KY, et al. SARS-CoV-2 viral dynamics in
acute infections. medRxiv [Preprint]; published December 02, 2020.
DOI:10.1101/2020.10.21.20217042.
298. Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, et al. Clinical Course and Molecular Viral Shedding
Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community
Treatment Center in the Republic of Korea. JAMA Internal Medicine, 2020; 180(11):1447-1452.
DOI:10.1001/jamainternmed.2020.3862.
299. Kociolek LK, Muller WJ, Yee R, Dien Bard J, Brown CA, Revell PA, et al. Comparison of Upper
Respiratory Viral Load Distributions in Asymptomatic and Symptomatic Children Diagnosed with
SARS-CoV-2 Infection in Pediatric Hospital Testing Programs. Journal of Clinical Microbiology, 2020;
59(1). DOI:10.1128/JCM.02593-20.
300. Turner F, Vandenberg A, Slepnev VI, Car S, Starritt RE, Seger MV, et al. Post-Disease
Divergence in SARS-CoV-2 RNA Detection between Nasopharyngeal, Anterior Nares and Saliva/Oral
Fluid Specimens - Significant Implications for Policy & Public Health. medRxiv [Preprint]; published
January 26, 2021. DOI:10.1101/2021.01.26.21250523.
301. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an
updated list of essential items for reporting diagnostic accuracy studies. British Medical Journal,
2015; 351:h5527. DOI:10.1136/bmj.h5527.

302. Paul-Ehrlich-Institute. Comparative evaluation of the sensitivities of SARSCoV-2 antigen rapid
tests Langen: Federal Institute for Vaccines and Biomedicines; 2020.

1563

 Table 1: Clinical accuracy data for Ag-RDTs against SARS-CoV-2

Author	Study location	Sample type	Sample condition	IFU conform	Sample size	Sensitivity	Specificity
AAZ, COVID-VIRO® (LFA)							
[287] Schwob, a35.3	Switzerland	NP	fresh	yes	324	84.1% (95% CI 76.9-89.7)	100% (95% CI 98.0*-100*)
Abbott, BinaxNOW™ (LFA)							
[224] Pollock, f17.1	USA	AN	fresh	yes	2308	77.4% (95% CI 72.2-82.1)	99.4% (95% CI 99.0-99.7)
[283] Pilarowski, a29.1	USA	AN/MT	fresh	yes	878	57.7% (95% CI 36.9*-76.6*)	100%* (95% CI 99.6*-100*)
[197] James, f23.1	USA	AN	fresh	yes	2339	56.6% (95% CI 48.3*-64.6*)	99.9% (95% CI 99.6*-100)
[217] Okoye, f51.1	USA	MT	fresh	yes	2645	53.3% (95% CI 37.9*-68.3*)	100% (95% CI 99.9-100)
Abbott, Panbio™ (LFA)							
[175] Domínguez Fernández, f49.1	Spain	unclear	fresh	unclear	30	95.0% (95% CI 75.1*-99.9*)	100% (95% CI 69.2*-100*)
[250] Alemany, a02.1	Spain	NP	banked	no	919	93.4% (95% CI 91.5-95.0)	100% (95% CI 95.8-100)
[184] FINDdx, f42.2	Germany	NP	fresh	yes	281	90.9% (95% CI 78.3*-97.5*)	99.2% (95% CI 97.0-99.9*)
[276] Merino-Amador, a25.1	Spain	NP	fresh	yes	958	90.5% (95% CI 87.0*-93.4*)	98.8% (95% CI 97.6*-99.5*)
[267] Krüger, a52.1	Germany	NP	fresh	yes	1034	87.5% (95% CI 79.6*-93.2*)	99.9% (95% CI 99.4-100)
[287] Schwob, a35.2	Switzerland	NP	fresh	yes	271	86.1% (95% CI 78.6-91.7)	100% (95% CI 97.6*-100*)
[235] Stokes, f65.1	Canada	NP	fresh	yes	1641	86.2%* (95% CI 81.5*-90.1*)	99.9% (95% CI 99.5-100)
[252] Berger, a05.1	Switzerland	NP	fresh	yes	535	85.5% (95% CI 78.0-91.2)	100% (95% CI 99.1-100)
[177] Faíco-Filho, f63.1	Brazil	NP	fresh	yes	127	84.3% (95% CI 73.6*-91.9*)	98.2%* (95% CI 90.6*-100*)
[196] Jääskeläinen, f50.3	Finland	NP	banked	no	190	82.9%* (95% CI 76.0*-88.5*)	100% (95% CI 90.7*-100*)
[247] Abdulrahman, a01.1	Bahrain	AN/MT	fresh	no	4183	82.1% (95% CI 79.2-84.8)	99.1% (95% CI 98.8-99.4)
[263] Gremmels, a12.2	Netherlands	NP	fresh	yes	208	81.0% (95% CI 69.1*-89.8*)	100% (95% CI 97.5-100)
[214] Ngo Nsoga, f28.1	Switzerland	OP	fresh	no	402	81.0% (95% CI 74.2-86.6)	99.1% (95% CI 96.9-99.9)
[245] Yin, f82.2	Belgium	NP	fresh	yes	101	80.8% (95% CI 68.1-89.2)	not provided
[249] Albert, a03.1	Spain	NP	fresh	yes	412	79.6% (95% CI 66.5*-89.4*)	100% (95% CI 99.0-100)
[250] Alemany, a02.2	Spain	AN/MT	banked	no	487	79.5% (95% CI 71.0-86.4)	98.6%* (95% CI 96.9-99.6)
[258] Fenollar, a11.1	France	NP	fresh	yes	341	75.5% (95% CI 69.0*-81.2*)	94.9% (95% CI 89.8*-97.9*)
[270] Linares, a20.1	Spain	NP	fresh	unclear	255	73.3% (95% CI 60.3*-83.9*)	100% (95% CI 98.1*-100*)
[263] Gremmels, a12.1	Netherlands	NP	fresh	yes	1367	72.7%* (95% CI 64.5-79.9)	100% (95% CI 99.7-100)
[192] Halfon, f18.1	France	NP	unclear	no	200	72.0% (95% CI 62.1*-80.5*)	99.0% (95% CI 94.6*-100)
[253] Bulilete, a07.1	Spain	NP	fresh	yes	1362*	71.4% (95% CI 63.2*-78.7)	99.8% (95% CI 99.4-99.9)
[165] Akingba, f30.1	Southafrica	NP	fresh	unclear	657*	69.7%* (95% CI 61.5*-77.0*)	99.4%* (95% CI 98.3*-99.9*)

[174] Del Vecchio, f66.1	Italy	unclear	fresh	unclear	1441	68.9% (95% CI 55.7-80.1)	99.9% (95% CI 99.6-100)
[178] Favresse, f31.2	Belgium	NP	fresh	no	188	67.7% (95% CI 57.4-76.9)	100% (95% CI 96.1-100)
[257] Drevinek, a10.1	Czech Republic	NP	fresh	yes	591	66.4% (95% CI 59.8*-72.5*)	100% (95% CI 99.0-100)
[205] L'Huillier, f72.1	Switzerland	NP	fresh	yes	822	65.5%* (95% CI 56.3*-74.0)	99.9%* (95% CI 99.2*-100)
[221] Pérez-García, f52.2	Spain	NP	banked	no	320	60.0% (95% CI 52.2-67.4)	100% (95% CI 97.6-100)
[248] Agullo, a56.1	Spain	NP	fresh	yes	652*	57.6%* (95% CI 48.7*-66.1*)	99.8% (95% CI 98.9*-100)
[267] Krüger, a52.2	Germany	OP	fresh	no	74	50.0% (95% CI 1.3-98.7)	100% (95% CI 94.9-100)
[286] Schildgen, a33.2	Germany	BAL/TW	unclear	no	73	50.0% (95% CI 34.2*-65.8*)	77.4% (95% CI 58.9*-90.4*)
[292] Torres, a37.1	Spain	NP	fresh	yes	634	48.1% (95% CI 36.7*-59.6*)	100% (95% CI 99.3-100)
[244] Wagenhäuser, f89.2	Germany	OP	fresh	no	1029	46.7% (95% CI 24.8-69.9)	99.6% (95% CI 99.0-99.9)
[243] Villaverde, f55.1	Spain	NP	fresh	yes	1620	45.4% (95% CI 34.1-57.2)	99.8% (95% CI 99.4-99.9)
[248] Agullo, a56.2	Spain	AN/MT	fresh	no	659	44.7% (95% CI 36.1-53.6)	100% (95% CI 99.3*-100)
[279] Olearo, a54.2	Germany	OP	unclear	no	184	44.0%* (95% CI 33.2*-55.3*)	100% (95% CI 96.4*-100)
[170] Caruana, f34.2	Switzerland	NP	fresh	no	532	41.2% (95% CI 32.1*-50.8*)	99.5% (95% CI 98.3*-99.9*)
[167] Baro, f33.1	Spain	NP	banked	no	286	38.6% (95% CI 29.1-48.8)	99.5% (95% CI 97.0-100)
[248] Agullo, a56.3	Spain	saliva	fresh	no	610	23.1% (95% CI 16.0*-31.7*)	100% (95% CI 99.2*-100)
[213] Muhi, f90.1	Australia	NP	fresh	yes	2413	not provided	100% (95% CI 99.7-100)
Abbott, Panbio™ (nasal sampling) (LFA)							
[184] FINDdx, f42.1	Germany	AN/MT	fresh	yes	281	86.4% (95% CI 72.6*-94.8*)	99.2% (95% CI 97.0-99.9*)
Access Bio, CareStart™ COVID-19 Antigen Test (LFA)							
[225] Pollock, f59.1	USA	AN	fresh	yes	1498	57.7% (95% CI 51.1-64.1)	98.3% (95% CI 97.5-99.0)
Assure Tech, Ecotest COVID-19 Antigen Rapid Test (LFA)							
[194] Homza, f87.1	Czech Republic	NP	fresh	yes	318	75.7% (95% CI 66.5-83.5)	96.7% (95% CI 93.3-98.7)
Becton, Dickinson and Company, BD Veritor™ (requires reader)							
[281] Pekosz, a28.1	USA	NP	fresh	no	251	96.4% (95% CI 81.7*-99.9*)	98.7% (95% CI 96.1-99.7)
[293] Van der Moeren, a39.1	Netherlands	MT/OP	banked	no	351*	94.1% (95% CI 71.1-100)	100% (95% CI 98.9-100)
[190] Marti, f46.2	USA	AN	fresh	unclear	unknown	93.8% (95% CI 79.2*-99.2*)	not provided
[245] Yin, f82.1	Belgium	NP	fresh	yes	177	87.7% (95% CI 80.0-92.7)	not provided
[296] Young, a43.1	USA	NP	banked	no	251	76.3%* (95% CI 59.8*-88.6*)	99.5%* (95% CI 97.4*-99.9*)
[202] Kilic, f71.1	USA	AN	fresh	yes	1384	66.4% (95% CI 57.0-74.9)	98.8% (95% CI 98.1-99.3)
[231] Schuit, f64.1	Netherlands	NP	fresh	no	2678	63.9% (95% CI 57.4-70.1)	99.6% (95% CI 99.3-99.8)
[170] Caruana, f34.4	Switzerland	NP	fresh	no	532	41.2% (95% CI 32.1*-50.8*)	99.8%* (95% CI 98.7*-100*)
Becton, Dickinson and Company, Hometest (LFA)							

Reference	Country	Sample	Status		N	Sensitivity	Specificity
[234] Stohr, f45.1	Netherlands	AN	fresh	unclear	1604	48.9% (95% CI 41.3*-56.5*)	99.9% (95% CI 99.5-100)

Beijing Savant Biotechnology, SARS-CoV-2 detection kit (LFA)

Reference	Country	Sample	Status		N	Sensitivity	Specificity
[295] Weitzel, a41.3	Chile	NP/OP	banked	no	109	16.7% (95% CI 9.2*-26.8*)	100% (95% CI 88.8*-100)

Biotime, COVID-19 Antigen Test Cassette (LFA)

Reference	Country	Sample	Status		N	Sensitivity	Specificity
[232] Seitz, f68.1	Austria	saliva	fresh	yes	40	44.4% (95% CI 21.5*-69.2*)	100% (95% CI 84.6*-100*)

Bionote, NowCheck® (LFA)

Reference	Country	Sample	Status		N	Sensitivity	Specificity
[185] FINDdx, f91.1	Brazil	AN	fresh	yes	218	89.9% (95% CI 81.0*-95.5*)	98.6% (95% CI 94.9-99.8*)
[185] FINDdx, f91.2	Brazil	NP	fresh	yes	218	89.9% (95% CI 81.0*-95.5*)	98.6% (95% CI 94.9-99.8*)
[259] FINDdx, a61.1	Brazil	NP	fresh	yes	400	89.2% (95% CI 81.5*-94.5*)	97.3% (95% CI 94.8-98.8*)
[228] Rottenstreich, f53.1	Israel	NP	unclear	unclear	1326	55.6% (95% CI 21.2-86.3)	100% (95% CI 99.7-100)

Biotical Health, SARS-CoV-2 Ag Card (LFA)

Reference	Country	Sample	Status		N	Sensitivity	Specificity
[178] Favresse, f31.1	Belgium	NP	fresh	no	188	66.7% (95% CI 56.3-76.0)	98.9% (95% CI 94.1-99.9)

CerTest Biotec, SARS-CoV-2 one step test card (LFA)

Reference	Country	Sample	Status		N	Sensitivity	Specificity
[221] Pérez-García, f52.1	Spain	NP	banked	no	320	53.5% (95% CI 45.7-61.2)	100% (95% CI 97.6-100)

Coris BioConcept, COVID-19 Ag Respi-Strip (LFA)

Reference	Country	Sample	Status		N	Sensitivity	Specificity
[245] Yin, f82.3	Belgium	NP	fresh	yes	135	80.0% (95% CI 69.2-87.7)	not provided
[277] Mertens, a48.1	Belgium	NP	banked	no	328	57.6% (95% CI 48.7*-66.1*)	99.5% (95% CI 97.2*-100*)
[269] Lambert-Niclot, a18.1	France	NP	fresh	no	138	50.0% (95% CI 39.5-60.5)	100% (95% CI 92.0*-100)
[4] Krüger, a17.3	Germany/England	NP/OP	unclear	no	417	50.0% (95% CI 21.5*-78.5)	95.8% (95% CI 93.4-97.4)
[172] Ciotti, f24.1	Italy	NP	fresh	unclear	50	30.8% (95% CI 17.0-47.6)	100% (95% CI 71.5-100)
[288] Scohy, a34.1	Belgium	NP	fresh	no	148	30.2% (95% CI 21.7-39.9)	100% (95% CI 91.6*-100*)
[294] Veyrenche, a40.1	France	NP	fresh	no	65	28.9%* (95% CI 16.4*-44.3*)	100% (95% CI 83.2-100)

Denka, Quick Navi (LFA)

Reference	Country	Sample	Status		N	Sensitivity	Specificity
[237] Takeuchi, f12.1	Japan	NP	fresh	unclear	1186	86.7% (95% CI 78.6-92.5)	100% (95% CI 99.7-100)
[238] Takeuchi, f60.1	Japan	AN	fresh	unclear	862	72.5% (95% CI 58.3-84.1)	100% (95% CI 99.5*-100)

DiaSorin, LIAISON® SARS-CoV-2 Ag (LFA)

Reference	Country	Sample	Status		N	Sensitivity	Specificity
[206] Lefever, f70.1	Belgium	NP	banked	no	414	67.6%* (95% CI 60.8*-74.0*)	100% (95% CI 98.3*-100)

Dräger, Antigen Test SARS-CoV-2 (LFA)

Reference	Country	Sample	Status		N	Sensitivity	Specificity
[218] Osmanodja, f79.1	Germany	NP/OP	fresh	yes	379	88.6% (95% CI 78.7-94.9)	99.7% (95% CI 98.2-100)

E25Bio, Rapid Diagnostic Test (LFA)

Reference	Country	Sample	Status		N	Sensitivity	Specificity
[223] Pickering, f73.2	United Kingdom	AN/OP	banked	no	200	75.0% (95% CI 65.3*-83.1*)	86% (95% CI 77.6*-92.1*)

EcoDiagnostica, COVID-19 Ag (LFA)

Reference	Country	Sample	Status		N	Sensitivity	Specificity
[180] Filgueiras, f14.1	Brazil	NP	fresh	unclear	150	69.1% (95% CI 55.2*-80.9*)	98.8% (95% CI 93.5*-100)

Fujirebio, ESPLINE® SARS-CoV-2 (LFA)

Reference	Country	Sample	Status		N	Sensitivity	Specificity
[290] Takeda, a50.1	Japan	NP	unclear	no	162	80.6%* (95% CI 68.6*-89.6*)	100%* (95% CI 96.4*-100*)
[186] FINDdx, f92.1	Germany	NP/OP	fresh	no	723	78.6% (95% CI 69.8*-85.8*)	100% (95% CI 99.4-100)

[230] Sberna, f83.1	Italy	saliva	unclear	unclear	136	8.1% (95% CI 2.7-17.8)	100% (95% CI 95.1-100)

Fujirebio, Lumipulse® G SARS-CoV-2 Ag (requires reader)						
[189] Gili, f57.2	Italy	NP	banked	no	226	100% (95% CI 96.0*-100*)	92.1% (95% CI 90.7*-93.4*)
[189] Gili, f57.1	Italy	NP	fresh	no	1738	90.5% (95% CI 82.8*-95.6*)	91.6% (95% CI 85.5*-95.7*)
[193] Hirotsu, f47.1	Japan	NP	banked	no	1033	92.5% (95% CI 79.6*-98.4*)	100%* (95% CI 99.6*-100*)
[168] Basso, f10.1	Italy	NP	fresh	yes	234	81.6% (95% CI 71.9*-89.1*)	93.9%* (95% CI 88.7*-97.2*)
[166] Asai, f74.1	Japan	saliva	unclear	yes	305	77.8% (95% CI 65.5*-87.3*)	98.3% (95% CI 95.8*-99.5*)
[168] Basso, f10.2	Italy	saliva	fresh	yes	223	41.3% (95% CI 30.4-52.8)	98.6% (95% CI 95.0-99.8)

Guangzhou Wondfo Biotech, 2019-nCoV Antigen Test (LFA)						
[183] FINDdx, f41.1	Switzerland	NP	fresh	yes	328	85.7% (95% CI 73.8*-93.6*)	100% (95% CI 98.7*-100*)

Humasis, COVID-19 Ag Test (LFA)						
[169] Bruzzone, f86.2	Italy	unclear	banked	no	21	85.7% (95% CI 63.7*-97*)	not provided

Healgen, Rapid COVID-19 Ag Test (LFA)						
[178] Favresse, f31.3	Belgium	NP	fresh	no	188	77.1% (95% CI 67.4-85.1)	96.7% (95% CI 90.8-99.3)

ichroma, COVID-19 AG (requires reader)						
[181] FINDdx, f39.1	Switzerland	NP	fresh	yes	232	73.2% (95% CI 57.1*-85.8*)	100% (95% CI 98.0-100)

Innova Medical Group, INNOVA SARS-CoV-2 Antigen Rapid Qualitative Test (LFA)						
[223] Pickering, f73.1	United Kingdom	AN/OP	banked	no	200	89.0% (95% CI 81.2*-94.4*)	99.0% (95% CI 94.6-100)
[195] Houston, f25.1	United Kingdom	NP	fresh	yes	242	86.4% (95% CI 81.9*-90.2*)	95.1% (95% CI 92.7*-96.9*)
[223] Pickering, f73.10	United Kingdom	AN/OP	banked	no	23	82.6% (95% CI 61.2*-95.0*)	not provided
[223] Pickering, f73.11	United Kingdom	AN/OP	banked	no	23	82.6% (95% CI 61.2*-95.0*)	not provided
[222] Peto, f21.1	United Kingdom	unclear	unclear	unclear	6954	not provided	99.7% (95% CI 99.5*-99.8*)
[222] Peto, f21.4	United Kingdom	unclear	unclear	unclear	198	78.8% (95% CI 72.4-84.3)	not provided
[223] Pickering, f73.12	United Kingdom	AN/OP	banked	no	23	78.3% (95% CI 56.3*-92.5*)	not provided
[223] Pickering, f73.8	United Kingdom	AN/OP	banked	no	110	78.2% (95% CI 69.3*-85.5*)	not provided
[222] Peto, f21.3	United Kingdom	unclear	unclear	unclear	223	70.0% (95% CI 63.5-75.9)	not provided
[246] Young, f56.1	United Kingdom	NP	fresh	unclear	803	62.1%*(95% CI 55.3*-68.7*)	100% (95% CI 99.4-100)
[222] Peto, f21.2	United Kingdom	unclear	unclear	unclear	372	57.5% (95% CI 52.3-62.6)	not provided
[179] Ferguson, f85.1	United Kingdom	AN	fresh	yes	720	3.2% (95% CI 0.6-15.6)	100% (95% CI 99.5-100)

JOYSBIO Biotechnology, COVID-19 Antigen Rapid Test Kit (LFA)						
[182] FINDdx, f40.1	Switzerland	NP	fresh	yes	265	70.5% (95% CI 54.8*-83.2*)	99.1% (95% CI 96.8*-99.9*)
[194] Homza, f87.2	Czech Republic	NP	fresh	yes	225	57.8% (95% CI 46.9-68.1)	98.5% (95% CI 94.8-99.8)

Lab Care Diagnostics, PathoCatch/ACCUCARE SARS-CoV-2 Antigen Test (LFA)						
[239] Thakur, f88.1	India	NP	fresh	yes	677	34.5% (95% CI 24.5-45.6)	99.8% (95% CI 99.1-100)

Lepu Medical, SARS-CoV-2 Antigen Rapid Test Kit (LFA)						
[167] Baro, f33.4	Spain	NP	banked	no	286	45.5% (95% CI 35.6-55.8)	89.2% (95% CI 83.8-93.3)
Liming Bio, SARS-CoV-2 Ag-RDT (LFA)						
[295] Weitzel, a41.2	Chile	NP/OP	banked	no	19	0% (95% CI 0-29.9)	90.0% (95% CI 59.6-98.2)
LumiraDx, COVID-19 SARS-CoV-2 Antigen Test (requires reader)						
[176] Drain, f43.1	UK/US	AN	fresh	yes	257	97.6% (95% CI 91.6*-99.7*)	96.6% (95% CI 92.6*-98.7*)
[176] Drain, f43.2	UK/US	NP	fresh	yes	255	97.5% (95% CI 86.8*-99.9*)	97.7% (95% CI 94.7-99.2*)
[204] Krüger, f58.1	Germany	MT	fresh	yes	761	82.2% (95% CI 75.0*-88.0*)	99.3% (95% CI 98.3-99.7)
[169] Bruzzone, f86.6	Italy	unclear	banked	no	23	69.6% (95% CI 47.1*-86.8*)	not provided
[203] Kohmer, f32.4	Germany	NP	fresh	no	100	50.0% (95% CI 38.1-61.9)	100% (95% CI 86.8-100)
[211] Micocci, f77.1	United Kingdom	NP	fresh	unclear	241	75.0%* (95% CI 34.9*-96.8*)	96.1%* (95% CI 92.7*-98.2*)
MEDsan®, SARS-CoV-2 Antigen Rapid Test (LFA)						
[279] Olearo, a54.3	Germany	OP	unclear	no	184	45.2%* (95% CI 34.3*-56.5)	97.0% (95% CI 91.5-99.4*)
[244] Wagenhäuser, f89.3	Germany	OP	fresh	yes	3221	36.5% (95% CI 24.7*-49.6*)	99.6% (95% CI 99.3-99.8)
MOLOGIC, COVID-19 Rapid Antigen Test (LFA)						
[187] FINDdx, f93.1	Germany	AN/NMT	fresh	yes	665	90.7% (95% CI 85.7*-94.4*)	100% (95% CI 99.2-100)
NAL von minden, NADAL (LFA)						
[188] FINDdx, f94.1	Switzerland	NP	fresh	yes	462	88.4% (95% CI 78.4*-94.9*)	99.2% (95% CI 97.8-99.7)
[236] Strömer, f11.1	Germany	NP	banked	no	124	63.7%* (95% CI 54.6*-72.2*)	not provided
[244] Wagenhäuser, f89.1	Germany	OP	fresh	yes	806	56.5% (95% CI 34.5*-76.8*)	100% (95% CI 99.5-100)
[203] Kohmer, f32.3	Germany	NP	fresh	no	100	24.3% (95% CI 15.1-35.7)	100% (95% CI 86.8-100)
NanoEntek, FREND™ COVID-19 Ag (requires reader)						
[169] Bruzzone, f86.7	Italy	unclear	banked	no	60	93.3% (95% CI 83.8*-98.2*)	not provided
NDFOS, ND COVID-19 Ag Test (LFA)						
[194] Homza, f87.3	Czech Republic	NP	fresh	yes	191	70.1% (95% CI 58.6-80.0)	56.1% (95% CI 46.4-65.4)
Ortho Clinical Diagnostics, VITROS® SARS-CoV-2 Antigen Test (requires reader)						
[178] Favresse, f31.5	Belgium	NP	fresh	no	188	83.3% (95% CI 74.4-90.2)	100% (95% CI 96.1-100)
Precision Biosensors, Exdia COVID-19 Ag (requires reader)						
[170] Caruana, f34.3	Switzerland	NP	fresh	no	532	48.3% (95% CI 38.8*-57.8*)	99.5% (95% CI 98.3*-99.9*)
PRIMA, COVID-19 Antigen Rapid Test (LFA)						
[169] Bruzzone, f86.3	Italy	unclear	banked	no	50	66.0% (95% CI 51.2*-78.8*)	not provided
QUIDEL, Sofia SARS Antigen FIA (requires reader)						
[284] Porte, a32.1	Chile	NP/OP	banked	no	64	93.8% (95% CI 79.2*-99.2*)	96.9% (95% CI 83.8*-99.9*)
[196] Jääskeläinen, f50.1	Finland	NP	banked	no	188	80.4% (95% CI 73.1*-86.5*)	100% (95% CI 91.2*-100*)
[251] Beck, a04.1	USA	NP	fresh	yes	346	77.0% (95% CI 64.5*-86.8*)	99.6% (95% CI 98.1*-100*)
[265] Herrera, a46.1	USA	unclear	unclear	unclear	1172	76.8% (95% CI	99.2% (95% CI

						72.6-80.5)	98.2-99.7)
[190] Marti, f46.1	USA	MT	fresh	unclear	427	72.0% (95% CI 56.3*-84.7*)	99.7%* (95% CI 98.6*-100*)

RapiGEN, Biocredit Covid-19 Antigen Detection Kit (LFA)

[289] Shrestha, a36.1	Nepal	NP	fresh	yes	113	85.0% (95% CI 71.7*-93.8*)	100% (95% CI 94.6*-100*)
[260] FINDdx, a62.1	Brazil	NP	fresh	yes	476	74.4% (95% CI 65.5*-82.0*)	98.9%* (95% CI 97.2-99.7*)
[295] Weitzel, a41.1	Chile	NP/OP	banked	no	109	62.0% (95% CI 50.4*-72.7*)	100% (95% CI 88.4*-100)
[233] Shidlovskaya, f61.1	Russia	NP	fresh	yes	106	56.4% (95% CI 44.7-67.6)	100% (95% CI 87.7-100)
[260] FINDdx, a62.2	Germany	ONP	fresh	yes	1239	52.0% (95% CI 31.3*-72.2*)	100% (95% CI 99.7-100)
[169] Bruzzone, f86.4	Italy	unclear	banked	no	23	39.1% (95% CI 19.7*-61.5*)	not provided
[286] Schildgen, a33.1	Germany	BAL/TW	unclear	no	73	33.3% (95% CI 19.6*-49.6*)	87.1% (95% CI 70.2*-96.4*)
[200] Kenyeres, f84.1	Hungary	NP	fresh	no	37	8.1% (95% CI 1.7*-21.9*)	not provided

R-Biopharm, RIDA®QUICK SARS-CoV-2 Antigen (LFA)

[291] Toptan, a55.1	Germany	NP/OP	banked	no	67	77.6% (95% CI 64.7*-87.5*)	100% (95% CI 66.4*-100*)
[291] Toptan, a55.2	Germany	unclear	banked	no	70	50.0% (95% CI 31.9*-68.1*)	100% (95% CI 90.8*-100*)
[203] Kohmer, f32.1	Germany	NP	fresh	no	100	39.2% (95% CI 28.0-51.2)	96.2% (95% CI 80.4-99.9)

Roche, Elecsys® SARS-CoV-2 Antigen Test (requires reader)

[216] Nörz, f78.1	Germany	NP/OP	banked	no	3139	60.2% (95% CI 55.2-65.1)	99.9% (95% CI 99.6-100)

Roche, SARS-CoV-2 Rapid Antigen Test (LFA)

[240] Thell, f81.1	Austria	unclear	fresh	unclear	591	80.3% (95% CI 74.3-85.4)	99.1% (95% CI 97.4-99.8)

SD Biosensor, Standard F (requires reader)

[284] Porte, a32.2	Chile	NP/OP	banked	no	64	90.6% (95% CI 75.0*-98.0*)	96.9% (95% CI 83.8*-99.9*)
[169] Bruzzone, f86.5	Italy	unclear	banked	no	60	86.7% (95% CI 75.4*-94.1*)	not provided
[261] FINDdx, a63.1	Brazil	NP	fresh	yes	453	77.5% (95% CI 69.0*-84.6*)	97.9% (95% CI 95.7-99.2*)
[261] FINDdx, a63.2	Germany	ONP	fresh	yes	676	69.2% (95% CI 52.4*-83.0*)	96.9% (95% CI 95.2-98.0)
[257] Drevinek, a10.2	Czech Republic	NP	fresh	yes	591	62.3% (95% CI 55.6*-68.7*)	99.5% (95% CI 98.0-99.9)
[219] Osterman, f20.1	Germany	NP/OP	unclear	no	360	60.9% (95% CI 53.5*-67.8*)	97.8% (95% CI 95.7-99.0*)
[273] Liotti, a22.1	Italy	NP	banked	no	359	47.1% (95% CI 37.1-57.1)	98.4% (95% CI 96.0-99.6)

SD Biosensor / Roche, Standard Q (LFA)

[255] Chaimayo, a57.1	Thailand	NP/OP	banked	no	454	98.3% (95% CI 91.1-100)	98.7% (95% CI 97.1-99.6)
[169] Bruzzone, f86.1	Italy	unclear	banked	no	16	93.8% (95% CI 71.7-98.9)	not provided
[201] Kerneis, f69.1	France	NP	fresh	unclear	1109	94.2%* (95% CI 87.0*-98.1*)	99.0% (95% CI 98.2*-99.5*)
[287] Schwob, a35.1	Switzerland	NP	fresh	yes	333	92.9% (95% CI 86.4-96.9)	100% (95% CI 98.3*-100*)
[215] Nikolai, f35.3	Germany	NP	fresh	yes	96	91.2% (95% CI 76.3*-98.1*)	100% (95% CI 94.2-100)
[252] Berger, a05.2	Switzerland	NP	fresh	yes	529	89.0% (95% CI 83.7-93.1)	99.7% (95% CI 98.4-100)

[262] FINDdx, a64.1	Brazil	NP	fresh	yes	400	88.7% (95% CI 81.1*-94.0*)	97.6% (95% CI 95.2-99.0*)
[286] Schildgen, a33.3	Germany	BAL/TW	unclear	no	73	88.1% (95% CI 74.4*-96.0*)	19.4% (95% CI 7.5*-37.5*)
[207] Lindner, f15.1	Germany	NP	fresh	yes	139	85.0% (95% CI 70.2*-94.3*)	99.1% (95% CI 94.9*-100*)
[266] Iglŏi, a15.1	Netherlands	NP	fresh	yes	970	84.9% (95% CI 79.0*-89.8*)	99.5% (95% CI 98.7-99.9*)
[264] Gupta, a13.1	India	NP	fresh	yes	330	81.8% (95% CI 71.4*-89.7*)	99.6% (95% CI 97.8-99.9)
[196] Jääskeläinen, f50.2	Finland	NP	banked	no	198	81.0% (95% CI 74.0*-86.8*)	100% (95% CI 91.2*-100*)
[242] Turcato, f09.1	Italy	NP	fresh	unclear	3410	80.3% (95% CI 74.4*-85.3*)	99.1% (95% CI 98.7*-99.4*)
[272] Lindner, a21.2	Germany	NP	fresh	yes	289	79.5% (95% CI 63.5*-90.7*)	99.6% (95% CI 97.8-100)
[245] Yin, f82.4	Belgium	NP	fresh	yes	65	78.3% (95% CI 58.1-90.3)	not provided
[4] Krüger, a17.1	Germany/England	NP/OP	unclear	no	1263	76.6% (95% CI 62.0*-87.7*)	99.3% (95% CI 98.6-99.7*)
[212] Möckel, f19.1	Germany	NP/OP	fresh	yes	271	75.3% (95% CI 65.0*-83.8*)	100% (95% CI 98.0*-100)
[272] Lindner, a21.1	Germany	AN/MT	fresh	no	289	74.4% (95% CI 57.9*87.0*)	99.2% (95% CI 97.1-99.9*)
[271] Lindner, a53.1	Germany	NP	fresh	yes	180	73.2%* (95% CI 57.1*-85.8*)	99.3% (95% CI 96.0-100)
[229] Salvagno, f54.1	Italy	NP	unclear	no	321	72.5% (95% CI 64.6-79.5)	99.4% (95% CI 96.8-100)
[254] Cerutti, a08.1	Italy	NP	unclear	no	185	72.1% (95% CI 62.5*-80.5*)	100% (95% CI 95.6*-100*)
[212] Möckel, f19.2	Germany	NP/OP	fresh	yes	2020	72.0% (95% CI 50.6*-87.9*)	99.4% (95% CI 96.9*-100*)
[268] Krüttgen, a16.1	Germany	NP	banked	no	150	70.7% (95% CI 59.0*-80.6*)	96.0% (95% CI 88.8*-99.2*)
[278] Nalumansi, a27.1	Uganda	NP	fresh	yes	262	70.0% (95% CI 59.4*-79.2*)	92.4%* (95% CI 87.4*-95.9*)
[220] Pena, f36.1	Chile	NP	fresh	yes	842	69.9% (95% CI 58.0*-80.1*)	99.6% (95% CI 98.9-99.9)
[178] Favresse, f31.4	Belgium	NP	fresh	no	188	69.8% (95% CI 59.6-78.8)	100% (95% CI 96.1-100)
[219] Osterman, f20.2	Germany	NP/OP	unclear	no	386	64.5% (95% CI 58.3*-70.3*)	97.7% (95% CI 95.6-98.9*)
[194] Homza, f87.4	Czech Republic	NP	fresh	yes	139	61.9% (95% CI 45.6-76.4)	99.0% (95% CI 94.4-100)
[231] Schuit, f64.2	Netherlands	NP	fresh	yes	1596	62.9% (95% CI 54.0-71.1)	99.5% (95% CI 98.9-99.8)
[226] Ristic, f44.1	Serbia	NP	fresh	unclear	120	58.1% (95% CI 42.1-73.0)	100% (95% CI 95.3*-100*)
[199] Kannian, f26.1	India	saliva	unclear	no	37	55.6%* (95% CI 35.3*-74.5*)	100% (95% CI 69.2*-100*)
[279] Olearo, a54.1	Germany	OP	unclear	no	184	48.8%* (95% CI 37.7*-60.0*)	100% (95% CI 96.4*-100)
[167] Baro, f33.3	Spain	NP	banked	no	286	43.6% (95% CI 33.7-53.8)	96.2% (95% CI 92.4-98.5)
[203] Kohmer, f32.2	Germany	NP	fresh	no	100	43.2% (95% CI 31.8*-55.3)	100% (95% CI 86.8-100)
[170] Caruana, f34.1	Switzerland	NP	fresh	no	532	41.2% (95% CI 32.1*-50.8*)	99.8%* (95% CI 98.7*-100*)
[254] Cerutti, a08.2	Italy	NP	fresh	no	145	40.0% (95% CI 5.3*-85.3*)	100% (95% CI 97.4*-100*)
[171] Caruana, f75.1	Switzerland	NP	fresh	unclear	116	28.6% (95% CI 3.7*-71.0*)	98.2% (95% CI 93.5*-99.8*)

SD Biosensor / Roche, Standard Q (nasal sampling) (LFA)

[215] Nikolai, f35.4	Germany	MT	fresh	yes	96	91.2% (95% CI 76.3*-98.1*)	98.4% (95% CI 91.3*-100*)
[215] Nikolai, f35.2	Germany	MT	fresh	yes	132	86.1% (95% CI 70.5*-95.3*)	100% (95% CI 96.2*-100*)
[215] Nikolai, f35.1	Germany	AN	fresh	yes	132	86.1% (95% CI 70.5*-95.3*)	100% (95% CI 96.2*-100*)
[207] Lindner, f15.2	Germany	MT	fresh	yes	180	82.5% (95% CI 67.2*92.7*)	100% (95% CI 96.5-100)
[234] Stohr, f45.2	Netherlands	AN	fresh	unclear	1611	61.5% (95% CI 54.2*-68.4*)	99.7% (95% CI 99.3-99.9)
[271] Lindner, a53.2	Germany	AN	fresh	yes	179	80.5% (95% CI 65.1*-91.2*)	98.6% (95% CI 94.9-99.8*)
Shenzhen Lvshiyuan Biotechnology, Green Spring® SARS-CoV-2-Antigen-Schnelltest-Set (LFA)							
[223] Pickering, f73.4	United Kingdom	AN/OP	banked	no	200	77.0% (95% CI 67.5*-84.8*)	98.0% (95% CI 93.0-99.8*)
Shenzen Bioeasy Biotechnology, 2019-nCov Antigen Rapid Test Kit (requires reader)							
[285] Porte, a31.1	Chile	NP/OP	banked	no	127	93.9% (95% CI 86.3*-98.0*)	100% (95% CI 92.1*-100*)
[295] Weitzel, a41.4	Chile	NP/OP	banked	no	111	85.0% (95% CI 75.3*-92.0*)	100% (95% CI 88.8*-100)
[282] Parada-Ricart, a58.1	Spain	NP	fresh	yes	172	73.1%* (95% CI 52.2*-88.4*)	85.6%* (95% CI 78.9*-90.9*)
[4] Krüger, a17.2	Germany	NP/OP	fresh	no	727*	66.7% (95% CI 41.7-84.8)	93.1% (95% CI 91.0-94.8)
Siemens Healthineers, CLINITEST® Rapid COVID-19 Antigen Test (LFA)							
[241] Torres, f29.1	Spain	NP	fresh	yes	178	80.2% (95% CI 70.6*-87.8*)	100% (95% CI 95.8-100)
[241] Torres, f29.2	Spain	NP	fresh	yes	92	60.0% (95% CI 38.7*-78.9*)	100% (95% CI 94.6-100)
[279] Olearo, a54.4	Germany	OP	unclear	no	170	54.8%* (95% CI 43.5*-65.7*)	100% (95% CI 95.8*-100*)
[167] Baro, f33.2	Spain	NP	banked	no	286	51.5% (95% CI 41.3-61.6)	98.4% (95% CI 95.3-99.7*)
SIENNA, COVID-19 Antigen Rapid Test (LFA)							
[209] Bouassa, f67.1	France	NP	banked	no	100	90.0% (95% CI 82.4*-95.1*)	100% (95% CI 92.9*-100)
Sugentech, SGTi-flex COVID-19 Ag (LFA)							
[233] Shidlovskaya, f61.2	Russia	NP	fresh	yes	106	52.6% (95% CI 40.9-64.0)	96.4% (95% CI 81.7-99.9)
SureScreen, COVID-19 Rapid Antigen Visual Read (LFA)							
[223] Pickering, f73.14	United Kingdom	AN/OP	banked	no	23	74.0%* (95% CI 51.6*-89.8*)	not provided
[223] Pickering, f73.3	United Kingdom	AN/OP	banked	no	200	65.0% (95% CI 54.8*-74.3*)	100% (95% CI 96.4*-100*)
[223] Pickering, f73.15	United Kingdom	AN/OP	banked	no	23	65.2% (95% CI 42.7*-83.6*)	not provided
[223] Pickering, f73.13	United Kingdom	AN/OP	banked	no	23	61.0%* (95% CI 38.5*-80.3*)	not provided
[167] Baro, f33.5	Spain	NP	banked	no	286	28.8% (95% CI 20.2-38.6)	97.8% (95% CI 94.5-99.4)
SureScreen, COVID-19 Rapid Antigen Flourescent (requires reader)							
[223] Pickering, f73.6	United Kingdom	AN/OP	banked	no	200	69.0% (95% CI 59.0*-77.9*)	98.0% (95% CI 93-99.8*)
[223] Pickering, f73.7	United Kingdom	AN/OP	banked	no	141	60.3% (95% CI 51.7*-68.4*)	not provided
VivaCheck, VivaDiag™ SARS-CoV-2 Ag Rapid Test (LFA)							
[194] Homza, f87.5	Czech Republic	NP	fresh	yes	268	41.8% (95% CI 31.5-52.6)	96.0% (95% CI 92.0-98.4)
Zhuhai Encode Medical Engineering, SARS-CoV-2 Antigen Rapid Test (LFA)							
[223] Pickering,	United Kingdom	AN/OP	banked	no	200	74.0% (95%	100% (95% CI

| f73.5 | | | | | | 64.3*-82.3*) | 96.4*-100) |
| [223] Pickering, f73.9 | United Kingdom | AN/OP | banked | no | 90 | 74.4% (95% CI 64.2*-83.1*) | not provided |

Caption: * Values differ from those provided in the respective manuscript due to missing or contradictory data. A list including the original data can be found in the Supplement (S4).

Data sets from an underlined author have not undergone peer-review yet (time of data extraction, 28.12.2020).

In data sets with underlined sample sizes the samples were used in head-to-head studies, performing different Ag-RDTs on the same patient.

Naming convention column "author": number in brackets relates to the list of sources. Letters behind the author's last name differentiates the data set from other data sets by the same author.

IFU = instructions for use; NP = nasopharyngeal; OP = oropharyngeal; AN = anterior nasal; MT = mid turbine; LRT = lower respiratory tract; BAL/TW = bronchoalveolar lavage and throat wash; CI = confidence interval.

1576   *Table 2:* Summary clinical accuracy data for major Ag-RDTs not included in the meta-analysis

Manufacturer, Ag-RDT	Number of data sets	Sensitivity range	Specifcity range	Comments
Bionote, NowCheck® (LFA)	3	55.6% to 89.9%	97.3% to 100%	- Two of the studies were IFU-conform, whereas IFU-conformity for the study reporting 55.6% sensitivity was unclear
Denka, Quick Navi (LFA)	2	72.5% to 86.7%	100%*	- Both studies were conducted on fresh samples, but for the one reporting 72.5% IFU-conformity was unclear
Fujirebio, ESPLINE® SARS-CoV-2 (LFA)	3	8.1% to 80.7%	100%*	- The data set reporting 8.1% sensitivity used saliva samples (not IFU-conform) and the majority of samples showed a Ct-value > 25
JOYSBIO Biotechnology, COVID-19 Antigen Rapid Test Kit (LFA)	2	57.8% to 70.5%	98.5% to 99.1%	- The datasets used NP and AN samples, respectively. Both were performed by IFU on symptomatic people or high-risk contacts
MEDsan®, SARS-CoV-2 Antigen Rapid Test (LFA)	2	36.5% to 45.2%	97% to 99.6%	- Both studies were conducted on OP samples, which is IFU-conforming for this test
R-Biopharm, RIDA®QUICK SARS-CoV-2 Antigen (lateral flow assay)	3	39.2% to 77.6%	96.2% to 100%	- Two data sets originate from the same study and no study was conducted as per IFU - The data set reporting 39.2% included only asymptomatic persons with Ct-values between 22.1 and 36.4
Shenzen Bioeasy Biotechnology, 2019-nCov Antigen Rapid Test Kit (requires reader)	4	66.7% to 93.9%	85.6% to 100%	- The data set reporting 85.6% specificity was conducted IFU-conforming - The data sets reporting highest sensitivity were drawn from just symptomatic patients, for the others symptomatic patients made up more than two thirds of the study population
SureScreen, COVID-19 Rapid Antigen Flourescent (requires reader)	2	60.3% to 69.0%	98%*	- Both datasets originate from the same study and were conducted not IFU-conforming on stored samples
Zhuhai Encode Medical Engineering, SARS-CoV-2 Antigen Rapid Test (LFA)	2	74.0% to 74.4%	100%*	- Both datasets originate from the same study, a retrospective head-to-head comparison - Stored AN/MT samples were assessed

1577

1578   *Caption:* * only one data set for specificity was provided
1579   IFU = instructions for use; Ag-RDT = antigen rapid diagnostic test; NP = nasopharyngeal; OP = oropharyngeal;
1580   AN = anterior nasal; MT = mid-turbinate.

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers and other sources

Test assessed	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)		
BD Veritor	6	6661	63.5% (49.3–75.8)	99.5% (98.8–99.8)		
BinaxNOW	4	8163	61.8% (48–74)	99.8% (99.5–99.9)		
CLINITEST	4	740	62.3% (47.4–75.2)	98.9% (97.1–99.6)		
Coris	5	729	40% (28.7–52.4)	98.5% (95.4–99.5)		
Lumipulse G	5	3532	87.2% (78–92.9)	96.7% (88.6–99.1)		
LumiraDx	4	1373	88.2% (59–97.5)	98.6% (96.2–99.5)		
Panbio	35	24472	71.8% (65.4–77.5)	99.4% (99.1–99.7)		
Rapigen	6	2116	62% (46.7–75.2)	98.5% (94–99.6)		
Sofia	5	2197	77.4% (74.2–80.3)	99.1% (98.3–99.5)		
Standard F	6	2692	68.1% (55.5–78.5)	97.7% (96.6–98.5)		
Standard Q	33	16478	74.9% (69.3–79.7)	98.6% (97.8–99.2)		
Standard Q nasal	6	2271	80.2% (70.3–87.4)	99% (97.7–99.6)		

Test assessed	Sensitivity N datasets	Sensitivity Total Sample Size	Pooled Sensitivity (95% CI)	Specificity N datasets	Specificity Total Sample Size	Pooled Specificity (95% CI)		
Innova	10	2686	76.1% (68.1–84.1)	4	8668	99.4% (98.7–100)		
Nadal	4	1492	58.4% (29.2–87.6)					
SureScreen V	4	269	65.9% (58.4–73.3)					

Testing procedure	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)		
IFU	81	49643	76.3% (73.1–79.2)	99.1% (98.8–99.4)		
non–IFU	75	31416	65.9% (60.6–70.8)	98.3% (97.7–98.8)		
unclear	17	14288	67.1% (55.8–76.7)	99.4% (99.2–99.6)		

Sample type	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)
AN/MT	32	25814	75.5% (70.4–79.9)	99.2% (98.7–99.5)
NP	122	59810	71.6% (68.1–74.9)	98.9% (98.5–99.1)
OP	7	5165	53.1% (40.9–65)	99.3% (98.2–99.7)
saliva	4	1088	37.9% (11.8–73.5)	99.2% (97.5–99.7)
unclear	5	3251	77.4% (71.8–82.2)	99.1% (97–99.7)

Symptoms	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)
Asymptomatic	25	15228	52.5% (43.7–61.1)	99.1% (98.3–99.5)
Symptomatic	38	17964	76.7% (70.6–81.9)	99% (98.5–99.4)
Symptoms <7 days	12	5538	83.8% (76.3–89.2)	99.3% (99–99.6)
Symptoms >=7 days	10	397	61.5% (52.2–70)	96.8% (93.5–98.5)

	N datasets	Total Sample Size	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)		
Age <18 years	7	3837	64.3% (54.7–72.9)	99.4% (98.9–99.7)		
Age >=18 years	16	7326	74.8% (66.5–81.6)	98.7% (97.2–99.4)		